Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Moussa Youdim

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Living Beings

Anatomy

Disorders

Parkinson Disease

Concepts & Ideas

Kinetics

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
82
Amit, Tamar
75
Riederer, Peter
32
Mandel, Silvia
27
Weinreb, Orly
24
Ben-Shachar, Dorit
24
Gerlach, Manfred
22
Hochberg, Ze'ev
20
Bar-Am, Orit
20
Barkey, Ronnie
18
Finberg, J P M
14
Jellinger, Kurt
12
Fridkin, Mati
12
Zheng, Hailin
11
Yogev-Falach, Merav
10
Reznichenko, Lydia

Sign-in to see all Coauthors

Publications

TOP 3
Fu Hongjun; Dou Juan; Li Wenming; Cui Wei; Mak Shinghung; Hu Qiansheng; Luo Jialie; Lam Colin S C; Pang Yuanping; Youdim Moussa B H; Han Yifan
Promising multifunctional anti-Alzheimer's dimer bis(7)-Cognitin acting as an activator of protein kinase C regulates activities of alpha-secretase and BACE-1 concurrently.
Fishman-Jacob Tali; Reznichenko Lydia; Youdim Moussa B H; Mandel Silvia A
A sporadic Parkinson disease model via silencing of the ubiquitin-proteasome/E3 ligase component SKP1A.
Kupershmidt Lana; Weinreb Orly; Amit Tamar; Mandel Silvia; Carri Maria Teresa; Youdim Moussa B H
Neuroprotective and neuritogenic activities of novel multimodal iron-chelating drugs in motor-neuron-like NSC-34 cells and transgenic mouse model of amyotrophic lateral sclerosis.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Moussa Youdim (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Fu Hongjun; Dou Juan; Li Wenming; Cui Wei; Mak Shinghung; Hu Qiansheng; Luo Jialie; Lam Colin S C; Pang Yuanping; Youdim Moussa B H; Han Yifan
Promising multifunctional anti-Alzheimer's dimer bis(7)-Cognitin acting as an activator of protein kinase C regulates activities of alpha-secretase and BACE-1 concurrently.
European journal of pharmacology 2009;623(1-3):14-21.
2009: Fishman-Jacob Tali; Reznichenko Lydia; Youdim Moussa B H; Mandel Silvia A
A sporadic Parkinson disease model via silencing of the ubiquitin-proteasome/E3 ligase component SKP1A.
The Journal of biological chemistry 2009;284(47):32835-45.
2009: Kupershmidt Lana; Weinreb Orly; Amit Tamar; Mandel Silvia; Carri Maria Teresa; Youdim Moussa B H
Neuroprotective and neuritogenic activities of novel multimodal iron-chelating drugs in motor-neuron-like NSC-34 cells and transgenic mouse model of amyotrophic lateral sclerosis.
The FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2009;23(11):3766-79.
2009: Chertkow Yael; Weinreb Orly; Youdim Moussa B H; Silver Henry
Molecular mechanisms underlying synergistic effects of SSRI-antipsychotic augmentation in treatment of negative symptoms in schizophrenia.
Journal of neural transmission (Vienna, Austria : 1996) 2009;116(11):1529-41.
2009: Weinreb Orly; Amit Tamar; Sagi Yotam; Drigues Noam; Youdim Moussa B H
Genomic and proteomic study to survey the mechanism of action of the anti-Parkinson's disease drug, rasagiline compared with selegiline, in the rat midbrain.
Journal of neural transmission (Vienna, Austria : 1996) 2009;116(11):1457-72.
2009: Ou Xiao-Ming; Lu Deyin; Johnson Chandra; Chen Kevin; Youdim Moussa B H; Rajkowska Grazyna; Shih Jean C
Glyceraldehyde-3-phosphate dehydrogenase-monoamine oxidase B-mediated cell death-induced by ethanol is prevented by rasagiline and 1-R-aminoindan.
Neurotoxicity research 2009;16(2):148-59.
2009: Zheng Hailin; Youdim Moussa B H; Fridkin Mati
Site-activated multifunctional chelator with acetylcholinesterase and neuroprotective-neurorestorative moieties for Alzheimer's therapy.
Journal of medicinal chemistry 2009;52(14):4095-8.
2009: Tazik Shawna; Johnson Shakevia; Lu Deyin; Johnson Chandra; Youdim Moussa B H; Stockmeier Craig A; Ou Xiao-Ming
Comparative neuroprotective effects of rasagiline and aminoindan with selegiline on dexamethasone-induced brain cell apoptosis.
Neurotoxicity research 2009;15(3):284-90.
2009: Bar-Am Orit; Weinreb Orly; Amit Tamar; Youdim Moussa B H
The novel cholinesterase-monoamine oxidase inhibitor and antioxidant, ladostigil, confers neuroprotection in neuroblastoma cells and aged rats.
Journal of molecular neuroscience : MN 2009;37(2):135-45.
2009: Weinreb Orly; Mandel Silvia; Bar-Am Orit; Yogev-Falach Merav; Avramovich-Tirosh Yael; Amit Tamar; Youdim Moussa B H
Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs.
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2009;6(1):163-74.
2009: Halperin Ilan; Morelli Micaela; Korczyn Amos D; Youdim Moussa B H; Mandel Silvia A
Biomarkers for evaluation of clinical efficacy of multipotential neuroprotective drugs for Alzheimer's and Parkinson's diseases.
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2009;6(1):128-40.
2009: Silver Henry; Chertkow Yael; Weinreb Orly; Danovich Lena; Youdim Moussa
Multifunctional pharmacotherapy: what can we learn from study of selective serotonin reuptake inhibitor augmentation of antipsychotics in negative-symptom schizophrenia?
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2009;6(1):86-93.
2009: Van der Schyf Cornelis J; Youdim Moussa B H
Multifunctional drugs as neurotherapeutics.
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2009;6(1):1-3.
2008: Mandel Silvia A; Amit Tamar; Kalfon Limor; Reznichenko Lydia; Weinreb Orly; Youdim Moussa B H
Cell signaling pathways and iron chelation in the neurorestorative activity of green tea polyphenols: special reference to epigallocatechin gallate (EGCG).
Journal of Alzheimer's disease : JAD 2008;15(2):211-22.
2008: Kleiner Yana; Bar-Am Orit; Amit Tamar; Berdichevski Alexandra; Liani Esti; Maor Gila; Reiter Irina; Youdim Moussa B H; Binah Ofer
TVP1022 and propargylamine protect neonatal rat ventricular myocytes against doxorubicin-induced and serum starvation-induced cardiotoxicity.
Journal of cardiovascular pharmacology 2008;52(3):268-77.
2008: Weinreb Orly; Bar-Am Orit; Amit Tamar; Drigues Noam; Sagi Yotam; Youdim Moussa B H
The neuroprotective effect of ladostigil against hydrogen peroxide-mediated cytotoxicity.
Chemico-biological interactions 2008;175(1-3):318-26.
2008: Youdim M B H
Brain iron deficiency and excess; cognitive impairment and neurodegeneration with involvement of striatum and hippocampus.
Neurotoxicity research 2008;14(1):45-56.
2008: Mandel Silvia A; Amit Tamar; Kalfon Limor; Reznichenko Lydia; Youdim Moussa B H
Targeting multiple neurodegenerative diseases etiologies with multimodal-acting green tea catechins.
The Journal of nutrition 2008;138(8):1578S-1583S.
2008: Weinreb Orly; Amit Tamar; Youdim Moussa B H
The application of proteomics for studying the neurorescue activity of the polyphenol (-)-epigallocatechin-3-gallate.
Archives of biochemistry and biophysics 2008;476(2):152-60.
2008: Zhu Wen; Xie Wenjie; Pan Tianhong; Jankovic Joseph; Li Jun; Youdim Moussa B H; Le Weidong
Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration.
Journal of neurochemistry 2008;105(5):1970-8.
2008: Amit Tamar; Avramovich-Tirosh Yael; Youdim Moussa B H; Mandel Silvia
Targeting multiple Alzheimer's disease etiologies with multimodal neuroprotective and neurorestorative iron chelators.
The FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2008;22(5):1296-305.
2008: Fu Hongjun; Li Wenming; Luo Jialie; Lee Nelson T K; Li Mingtao; Tsim Karl W K; Pang Yuanping; Youdim Moussa B H; Han Yifan
Promising anti-Alzheimer's dimer bis(7)-tacrine reduces beta-amyloid generation by directly inhibiting BACE-1 activity.
Biochemical and biophysical research communications 2008;366(3):631-6.
2008: Blat Dan; Weiner Lev; Youdim Moussa B H; Fridkin Mati
A Novel iron-chelating derivative of the neuroprotective peptide NAPVSIPQ shows superior antioxidant and antineurodegenerative capabilities.
Journal of medicinal chemistry 2008;51(1):126-34.
2008: Avramovich-Tirosh Yael; Amit Tamar; Bar-Am Orit; Weinreb Orly; Youdim Moussa B H
Physiological and pathological aspects of Abeta in iron homeostasis via 5'UTR in the APP mRNA and the therapeutic use of iron-chelators.
BMC neuroscience 2008;9 Suppl 2():S2.
2008: Mandel Silvia A; Amit Tamar; Weinreb Orly; Reznichenko Lydia; Youdim Moussa B H
Simultaneous manipulation of multiple brain targets by green tea catechins: a potential neuroprotective strategy for Alzheimer and Parkinson diseases.
CNS neuroscience & therapeutics 2008;14(4):352-65.
2008: Riederer P; Youdim M B H; Mandel S; Gerlach M; Grünblatt E
Genomic aspects of sporadic Parkinson's disease.
Parkinsonism & related disorders 2008;14 Suppl 2():S88-91.
2008: Weinreb Orly; Amit Tamar; Bar-Am Orit; Yogev-Falach Merav; Youdim Moussa B H
The neuroprotective mechanism of action of the multimodal drug ladostigil.
Frontiers in bioscience : a journal and virtual library 2008;13():5131-7.
2007: Van der Schyf Cornelis J; Mandel Silvia; Geldenhuys Werner J; Amit Tamar; Avramovich Yael; Zheng Hailin; Fridkin Mati; Gal Shunit; Weinreb Orly; Bar Am Orit; Sagi Yotam; Youdim Moussa B H
Novel multifunctional anti-Alzheimer drugs with various CNS neurotransmitter targets and neuroprotective moieties.
Current Alzheimer research 2007;4(5):522-36.
2007: Weinreb Orly; Amit Tamar; Bar-Am Orit; Youdim Moussa B H
Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy.
Annals of the New York Academy of Sciences 2007;1122():155-68.
2007: Zhu Wen; Xie Wenjie; Pan Tianhong; Xu Pingyi; Fridkin Mati; Zheng Hailin; Jankovic Joseph; Youdim Moussa B H; Le Weidong
Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators.
The FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2007;21(14):3835-44.
2007: Kupershmidt Lana; Amit Tamar; Bar-Am Orit; Youdim Moussa B H; Blumenfeld Zeev
The neuroprotective effect of Activin A and B: implication for neurodegenerative diseases.
Journal of neurochemistry 2007;103(3):962-71.
2007: Chertkow Yael; Weinreb Orly; Youdim Moussa B H; Silver Henry
Gene expression changes in peripheral mononuclear cells from schizophrenic patients treated with a combination of antipsychotic with fluvoxamine.
Progress in neuro-psychopharmacology & biological psychiatry 2007;31(7):1356-62.
2007: Bar-Am Orit; Amit Tamar; Youdim Moussa B H
Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro.
Journal of neurochemistry 2007;103(2):500-8.
2007: Avramovich-Tirosh Yael; Reznichenko Lydia; Mit Tamar; Zheng Hailin; Fridkin Mati; Weinreb Orly; Mandel Silvia; Youdim Moussa B H
Neurorescue activity, APP regulation and amyloid-beta peptide reduction by novel multi-functional brain permeable iron- chelating- antioxidants, M-30 and green tea polyphenol, EGCG.
Current Alzheimer research 2007;4(4):403-11.
2007: Mandel Silvia; Amit Tamar; Bar-Am Orit; Youdim Moussa B H
Iron dysregulation in Alzheimer's disease: multimodal brain permeable iron chelating drugs, possessing neuroprotective-neurorescue and amyloid precursor protein-processing regulatory activities as therapeutic agents.
Progress in neurobiology 2007;82(6):348-60.
2007: Weinreb Orly; Amit Tamar; Youdim Moussa B H
A novel approach of proteomics and transcriptomics to study the mechanism of action of the antioxidant-iron chelator green tea polyphenol (-)-epigallocatechin-3-gallate.
Free radical biology & medicine 2007;43(4):546-56.
2007: Kalfon Limor; Youdim Moussa B H; Mandel Silvia A
Green tea polyphenol (-) -epigallocatechin-3-gallate promotes the rapid protein kinase C- and proteasome-mediated degradation of Bad: implications for neuroprotection.
Journal of neurochemistry 2007;100(4):992-1002.
2007: Weinreb Orly; Drigues Noam; Sagi Yotam; Reznick Abraham Z; Amit Tamar; Youdim Moussa B H
The application of proteomics and genomics to the study of age-related neurodegeneration and neuroprotection.
Antioxidants & redox signaling 2007;9(2):169-79.
2007: Youdim M B H; Grünblatt E; Mandel S
The copper chelator, D-penicillamine, does not attenuate MPTP induced dopamine depletion in mice.
Journal of neural transmission (Vienna, Austria : 1996) 2007;114(2):205-9.
2007: Avramovich-Tirosh Yael; Amit Tamar; Bar-Am Orit; Zheng Hailin; Fridkin Mati; Youdim Moussa B H
Therapeutic targets and potential of the novel brain- permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer's disease.
Journal of neurochemistry 2007;100(2):490-502.
2007: Sagi Yotam; Mandel Silvia; Amit Tamar; Youdim Moussa B H
Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism.
Neurobiology of disease 2007;25(1):35-44.
2007: Youdim Moussa B H; Riederer Peter F
Monoamine oxidase A and B inhibitors in Parkinson's disease.
Handbook of clinical neurology / edited by P.J. Vinken and G.W. Bruyn 2007;84():93-120.
2007: Youdim Moussa B H; Geldenhuys Werner J; Van der Schyf Cornelis J
Why should we use multifunctional neuroprotective and neurorestorative drugs for Parkinson's disease?
Parkinsonism & related disorders 2007;13 Suppl 3():S281-91.
2007: Mandel Silvia A; Fishman Tali; Youdim Moussa B H
Gene and protein signatures in sporadic Parkinson's disease and a novel genetic model of PD.
Parkinsonism & related disorders 2007;13 Suppl 3():S242-7.
2007: Weinreb Orly; Youdim Moussa B H
A model of MPTP-induced Parkinson's disease in the goldfish.
Nature protocols 2007;2(11):3016-21.
2007: Chertkow Y; Weinreb O; Youdim M B H; Silver H
Dopamine and serotonin metabolism in response to chronic administration of fluvoxamine and haloperidol combined treatment.
Journal of neural transmission (Vienna, Austria : 1996) 2007;114(11):1443-54.
2006: Youdim Moussa B H; Amit Tamar; Bar-Am Orit; Weinreb Orly; Yogev-Falach Mara
Implications of co-morbidity for etiology and treatment of neurodegenerative diseases with multifunctional neuroprotective-neurorescue drugs; ladostigil.
Neurotoxicity research 2006;10(3-4):181-92.
2006: Youdim Moussa B H
The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and m30.
Current Alzheimer research 2006;3(5):541-50.
2006: Van der Schyf Cornelis J; Geldenhuys Werner J; Youdim Moussa B H
Multifunctional drugs with different CNS targets for neuropsychiatric disorders.
Journal of neurochemistry 2006;99(4):1033-48.
2006: Finberg J P M; Gross A; Bar-Am O; Friedman R; Loboda Y; Youdim M B H
Cardiovascular responses to combined treatment with selective monoamine oxidase type B inhibitors and L-DOPA in the rat.
British journal of pharmacology 2006;149(6):647-56.
2006: Yogev-Falach Merav; Bar-Am Orit; Amit Tamar; Weinreb Orly; Youdim Moussa B H
A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo-APP translation and processing.
The FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2006;20(12):2177-9.
2006: Bartels Anna L; de Jong Bauke M; Giladi Nir; Schaafsma Joanna D; Maguire R Paul; Veenma Lammy; Pruim Jan; Balash Yacov; Youdim Moussa B H; Leenders Klaus L
Striatal dopa and glucose metabolism in PD patients with freezing of gait.
Movement disorders : official journal of the Movement Disorder Society 2006;21(9):1326-32.
2006: Van der Schyf Cornelis J; Gal Shunit; Geldenhuys Werner J; Youdim Moussa B H
Multifunctional neuroprotective drugs targeting monoamine oxidase inhibition, iron chelation, adenosine receptors, and cholinergic and glutamatergic action for neurodegenerative diseases.
Expert opinion on investigational drugs 2006;15(8):873-86.
2006: Chertkow Yael; Weinreb Orly; Youdim Moussa B H; Silver Henry
The effect of chronic co-administration of fluvoxamine and haloperidol compared to clozapine on the GABA system in the rat frontal cortex.
The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP) 2006;9(3):287-96.
2006: Youdim Moussa B H; Edmondson Dale; Tipton Keith F
The therapeutic potential of monoamine oxidase inhibitors.
Nature reviews. Neuroscience 2006;7(4):295-309.
2006: Reznichenko L; Amit T; Zheng H; Avramovich-Tirosh Y; Youdim M B H; Weinreb O; Mandel S
Reduction of iron-regulated amyloid precursor protein and beta-amyloid peptide by (-)-epigallocatechin-3-gallate in cell cultures: implications for iron chelation in Alzheimer's disease.
Journal of neurochemistry 2006;97(2):527-36.
2006: Berg Daniela; Youdim Moussa B H
Role of iron in neurodegenerative disorders.
Topics in magnetic resonance imaging : TMRI 2006;17(1):5-17.
2006: Mandel Silvia; Amit Tamar; Reznichenko Lydia; Weinreb Orly; Youdim Moussa B H
Green tea catechins as brain-permeable, natural iron chelators-antioxidants for the treatment of neurodegenerative disorders.
Molecular nutrition & food research 2006;50(2):229-34.
2006: Youdim Moussa B H; Bakhle Y S
Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness.
British journal of pharmacology 2006;147 Suppl 1():S287-96.
2006: Yi H; Maruyama W; Akao Y; Takahashi T; Iwasa K; Youdim M B H; Naoi M
N-Propargylamine protects SH-SY5Y cells from apoptosis induced by an endogenous neurotoxin, N-methyl(R)salsolinol, through stabilization of mitochondrial membrane and induction of anti-apoptotic Bcl-2.
Journal of neural transmission (Vienna, Austria : 1996) 2006;113(1):21-32.
2006: Bandyopadhyay S; Huang X; Cho H; Greig N H; Youdim M B; Rogers J T
Metal specificity of an iron-responsive element in Alzheimer's APP mRNA 5'untranslated region, tolerance of SH-SY5Y and H4 neural cells to desferrioxamine, clioquinol, VK-28, and a piperazine chelator.
Journal of neural transmission. Supplementum 2006;(71):237-47.
2006: Youdim M B H
My love with monoamine oxidase, iron and Parkinson's disease.
Journal of neural transmission. Supplementum 2006;(71):V-IX.
2006: Weinreb O; Amit T; Bar-Am O; Sagi Y; Mandel S; Youdim M B H
Involvement of multiple survival signal transduction pathways in the neuroprotective, neurorescue and APP processing activity of rasagiline and its propargyl moiety.
Journal of neural transmission. Supplementum 2006;(70):457-65.
2006: Gal S; Fridkin M; Amit T; Zheng H; Youdim M B H
M30, a novel multifunctional neuroprotective drug with potent iron chelating and brain selective monoamine oxidase-ab inhibitory activity for Parkinson's disease.
Journal of neural transmission. Supplementum 2006;(70):447-56.
2006: Gerlach M; Double K L; Youdim M B H; Riederer P
Potential sources of increased iron in the substantia nigra of parkinsonian patients.
Journal of neural transmission. Supplementum 2006;(70):133-42.
2005: Zheng Hailin; Youdim Moussa B H; Weiner Lev M; Fridkin Mati
Novel potential neuroprotective agents with both iron chelating and amino acid-based derivatives targeting central nervous system neurons.
Biochemical pharmacology 2005;70(11):1642-52.
2005: Bar-Am Orit; Weinreb Orly; Amit Tamar; Youdim Moussa B H
Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine.
The FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2005;19(13):1899-901.
2005: Gal Shunit; Zheng Hailin; Fridkin Mati; Youdim Moussa B H
Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion.
Journal of neurochemistry 2005;95(1):79-88.
2005: Zheng Hailin; Gal Shunit; Weiner Lev M; Bar-Am Orit; Warshawsky Abraham; Fridkin Mati; Youdim Moussa B H
Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition.
Journal of neurochemistry 2005;95(1):68-78.
2005: Zheng H; Youdim M B H; Weiner L M; Fridkin M
Synthesis and evaluation of peptidic metal chelators for neuroprotection in neurodegenerative diseases.
The journal of peptide research : official journal of the American Peptide Society 2005;66(4):190-203.
2005: Sagi Yotam; Driguès Noam; Youdim Moussa B H
The neurochemical and behavioral effects of the novel cholinesterase-monoamine oxidase inhibitor, ladostigil, in response to L-dopa and L-tryptophan, in rats.
British journal of pharmacology 2005;146(4):553-60.
2005: Mandel Silvia; Packer Lester; Youdim Moussa B H; Weinreb Orly
Proceedings from the "Third International Conference on Mechanism of Action of Nutraceuticals".
The Journal of nutritional biochemistry 2005;16(9):513-20.
2005: Mandel Silvia; Grunblatt Edna; Riederer Peter; Amariglio Ninette; Jacob-Hirsch Jasmine; Rechavi Gideon; Youdim Moussa B H
Gene expression profiling of sporadic Parkinson's disease substantia nigra pars compacta reveals impairment of ubiquitin-proteasome subunits, SKP1A, aldehyde dehydrogenase, and chaperone HSC-70.
Annals of the New York Academy of Sciences 2005;1053():356-75.
2005: Weinreb Orly; Amit Tamar; Bar-Am Orit; Chillag-Talmor Orly; Youdim Moussa B H
Novel neuroprotective mechanism of action of rasagiline is associated with its propargyl moiety: interaction of Bcl-2 family members with PKC pathway.
Annals of the New York Academy of Sciences 2005;1053():348-55.
2005: Youdim Moussa B H; Maruyama Wakako; Naoi Makato
Neuropharmacological, neuroprotective and amyloid precursor processing properties of selective MAO-B inhibitor antiparkinsonian drug, rasagiline.
Drugs of today (Barcelona, Spain : 1998) 2005;41(6):369-91.
2005: Reznichenko L; Amit T; Youdim M B H; Mandel S
Green tea polyphenol (-)-epigallocatechin-3-gallate induces neurorescue of long-term serum-deprived PC12 cells and promotes neurite outgrowth.
Journal of neurochemistry 2005;93(5):1157-67.
2005: Mandel Silvia; Weinreb Orly; Amit Tamar; Youdim Moussa B H
Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives.
Brain research. Brain research reviews 2005;48(2):379-87.
2005: Youdim M B H; Buccafusco J J
CNS Targets for multi-functional drugs in the treatment of Alzheimer's and Parkinson's diseases.
Journal of neural transmission (Vienna, Austria : 1996) 2005;112(4):519-37.
2005: Zheng Hailin; Weiner Lev M; Bar-Am Orit; Epsztejn Silvina; Cabantchik Z Ioav; Warshawsky Abraham; Youdim Moussa B H; Fridkin Mati
Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases.
Bioorganic & medicinal chemistry 2005;13(3):773-83.
2005: Youdim Moussa B H; Fridkin Mati; Zheng Hailin
Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.
Mechanisms of ageing and development 2005;126(2):317-26.
2005: Youdim Moussa B H; Buccafusco Jerry J
Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders.
Trends in pharmacological sciences 2005;26(1):27-35.
2005: Youdim Moussa B H; Bar Am Orit; Yogev-Falach Merav; Weinreb Orly; Maruyama Wakako; Naoi Makato; Amit Tamar
Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition.
Journal of neuroscience research 2005;79(1-2):172-9.
2005: Mandel Silvia A; Avramovich-Tirosh Yael; Reznichenko Lydia; Zheng Hailin; Weinreb Orly; Amit Tamar; Youdim Moussa B H
Multifunctional activities of green tea catechins in neuroprotection. Modulation of cell survival genes, iron-dependent oxidative stress and PKC signaling pathway.
Neuro-Signals 2005;14(1-2):46-60.
2004: Grünblatt E; Mandel S; Jacob-Hirsch J; Zeligson S; Amariglo N; Rechavi G; Li J; Ravid R; Roggendorf W; Riederer P; Youdim M B H
Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes.
Journal of neural transmission (Vienna, Austria : 1996) 2004;111(12):1543-73.
2004: Zecca Luigi; Youdim Moussa B H; Riederer Peter; Connor James R; Crichton Robert R
Iron, brain ageing and neurodegenerative disorders.
Nature reviews. Neuroscience 2004;5(11):863-73.
2004: Youdim M B H; Fridkin M; Zheng H
Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases.
Journal of neural transmission (Vienna, Austria : 1996) 2004;111(10-11):1455-71.
2004: Riederer P F; Hirsch E; Youdim M B H; Calne D B
A tribute for Prof. Dr. Melvin D. Yahr, M.D. (1917-2004).
Journal of neural transmission (Vienna, Austria : 1996) 2004;111(10-11):1205-8.
2004: Youdim Moussa B H; Riederer Peter F
A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson's disease.
Neurology 2004;63(7 Suppl 2):S32-5.
2004: Berg Daniela; Youdim Moussa B H; Riederer Peter
Redox imbalance.
Cell and tissue research 2004;318(1):201-13.
2004: Abassi Zaid A; Binah Ofer; Youdim Moussa B H
Cardiovascular activity of rasagiline, a selective and potent inhibitor of mitochondrial monoamine oxidase B: comparison with selegiline.
British journal of pharmacology 2004;143(3):371-8.
2004: Weinreb Orly; Mandel Silvia; Amit Tamar; Youdim Moussa B H
Neurological mechanisms of green tea polyphenols in Alzheimer's and Parkinson's diseases.
The Journal of nutritional biochemistry 2004;15(9):506-16.
2004: Weinreb Orly; Bar-Am Orit; Amit Tamar; Chillag-Talmor Orly; Youdim Moussa B H
Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members.
The FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2004;18(12):1471-3.
2004: Mandel Silvia; Youdim Moussa B H
Catechin polyphenols: neurodegeneration and neuroprotection in neurodegenerative diseases.
Free radical biology & medicine 2004;37(3):304-17.
2004: Bar-Am Orit; Yogev-Falach Merav; Amit Tamar; Sagi Yotam; Youdim Moussa B H
Regulation of protein kinase C by the anti-Parkinson drug, MAO-B inhibitor, rasagiline and its derivatives, in vivo.
Journal of neurochemistry 2004;89(5):1119-25.
2004: Youdim Moussa B H; Arraf Zaher
Prevention of MPTP (N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) dopaminergic neurotoxicity in mice by chronic lithium: involvements of Bcl-2 and Bax.
Neuropharmacology 2004;46(8):1130-40.
2004: Youdim Moussa B H; Stephenson Galia; Ben Shachar Dorit
Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28.
Annals of the New York Academy of Sciences 2004;1012():306-25.
2004: Götz Mario E; Double Kay; Gerlach Manfred; Youdim Moussa B H; Riederer Peter
The relevance of iron in the pathogenesis of Parkinson's disease.
Annals of the New York Academy of Sciences 2004;1012():193-208.
2004: Shoham S; Youdim M B H
Nutritional iron deprivation attenuates kainate-induced neurotoxicity in rats: implications for involvement of iron in neurodegeneration.
Annals of the New York Academy of Sciences 2004;1012():94-114.
2004: Hubálek Frantisek; Binda Claudia; Li Min; Herzig Yaacov; Sterling Jeffrey; Youdim Moussa B H; Mattevi Andrea; Edmondson Dale E
Inactivation of purified human recombinant monoamine oxidases A and B by rasagiline and its analogues.
Journal of medicinal chemistry 2004;47(7):1760-6.
2004: Mandel Silvia; Weinreb Orly; Amit Tamar; Youdim Moussa B H
Cell signaling pathways in the neuroprotective actions of the green tea polyphenol (-)-epigallocatechin-3-gallate: implications for neurodegenerative diseases.
Journal of neurochemistry 2004;88(6):1555-69.
2004: Frölich L; Götz M E; Weinmüller M; Youdim M B H; Barth N; Dirr A; Gsell W; Jellinger K; Beckmann H; Riederer P
(r)-, but not (s)-alpha lipoic acid stimulates deficient brain pyruvate dehydrogenase complex in vascular dementia, but not in Alzheimer dementia.
Journal of neural transmission (Vienna, Austria : 1996) 2004;111(3):295-310.
2004: Shachar Dorit Ben; Kahana Nava; Kampel Vladimir; Warshawsky Abraham; Youdim Moussa B H
Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats.
Neuropharmacology 2004;46(2):254-63.
2004: Bar Am Orit; Amit Tamar; Youdim Moussa B H
Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline.
Neuroscience letters 2004;355(3):169-72.
2004: Matsukawa Motomi; Hirai Toshikazu; Karita Shoko; Akizawa Toshifumi; Pan-Hou Hidemitsu; Yoshioka Masanori; Goto Giichi; Parvez Hasan; Youdim Moussa B H
A screening system of prodrugs selective for MAO-A or MAO-B.
Neurotoxicology 2004;25(1-2):293-302.
2004: Youdim Moussa B H; Weinstock Marta
Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation.
Neurotoxicology 2004;25(1-2):243-50.
2004: Mandel Silvia; Maor Gila; Youdim Moussa B H
Iron and alpha-synuclein in the substantia nigra of MPTP-treated mice: effect of neuroprotective drugs R-apomorphine and green tea polyphenol (-)-epigallocatechin-3-gallate.
Journal of molecular neuroscience : MN 2004;24(3):401-16.
2003: Drigues N; Poltyrev T; Bejar C; Weinstock M; Youdim M B H
cDNA gene expression profile of rat hippocampus after chronic treatment with antidepressant drugs.
Journal of neural transmission (Vienna, Austria : 1996) 2003;110(12):1413-36.
2003: Yogev-Falach Merav; Amit Tamar; Bar-Am Orit; Youdim Moussa B H
The importance of propargylamine moiety in the anti-Parkinson drug rasagiline and its derivatives in MAPK-dependent amyloid precursor protein processing.
The FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2003;17(15):2325-7.
2003: Youdim Moussa B H; Amit Tamar; Falach-Yogev Merav; Bar Am Orit; Maruyama Wakkako; Naoi Makato
The essentiality of Bcl-2, PKC and proteasome-ubiquitin complex activations in the neuroprotective-antiapoptotic action of the anti-Parkinson drug, rasagiline.
Biochemical pharmacology 2003;66(8):1635-41.
2003: Double Kay L; Gerlach Manfred; Schünemann Volker; Trautwein Alfred X; Zecca Luigi; Gallorini Mario; Youdim Moussa B H; Riederer Peter; Ben-Shachar Dorit
Iron-binding characteristics of neuromelanin of the human substantia nigra.
Biochemical pharmacology 2003;66(3):489-94.
2003: Sagi Yotam; Weinstock Marta; Youdim Moussa B H
Attenuation of MPTP-induced dopaminergic neurotoxicity by TV3326, a cholinesterase-monoamine oxidase inhibitor.
Journal of neurochemistry 2003;86(2):290-7.
2003: Weinstock Marta; Gorodetsky Elena; Poltyrev Tatyana; Gross Aviva; Sagi Yotam; Youdim Moussa
A novel cholinesterase and brain-selective monoamine oxidase inhibitor for the treatment of dementia comorbid with depression and Parkinson's disease.
Progress in neuro-psychopharmacology & biological psychiatry 2003;27(4):555-61.
2003: Youdim Moussa B H; Amit Tamar; Bar-Am Orit; Weinstock Marta; Yogev-Falach Merav
Amyloid processing and signal transduction properties of antiparkinson-antialzheimer neuroprotective drugs rasagiline and TV3326.
Annals of the New York Academy of Sciences 2003;993():378-86; discussion 387-93.
2003: Weinreb Orly; Mandel Silvia; Youdim Moussa B H
Gene and protein expression profiles of anti- and pro-apoptotic actions of dopamine, R-apomorphine, green tea polyphenol (-)-epigallocatechine-3-gallate, and melatonin.
Annals of the New York Academy of Sciences 2003;993():351-61; discussion 387-93.
2003: Maruyama Wakako; Weinstock Marta; Youdim Moussa B H; Nagai Masayo; Naoi Makoto
Anti-apoptotic action of anti-Alzheimer drug, TV3326 [(N-propargyl)-(3R)-aminoindan-5-yl]-ethyl methyl carbamate, a novel cholinesterase-monoamine oxidase inhibitor.
Neuroscience letters 2003;341(3):233-6.
2003: Levites Yona; Amit Tamar; Mandel Silvia; Youdim Moussa B H
Neuroprotection and neurorescue against Abeta toxicity and PKC-dependent release of nonamyloidogenic soluble precursor protein by green tea polyphenol (-)-epigallocatechin-3-gallate.
The FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2003;17(8):952-4.
2003: Weinreb Orly; Mandel Silvia; Youdim Moussa B H
cDNA gene expression profile homology of antioxidants and their antiapoptotic and proapoptotic activities in human neuroblastoma cells.
The FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2003;17(8):935-7.
2003: Mandel Silvia; Weinreb Orly; Youdim Moussa B H
Using cDNA microarray to assess Parkinson's disease models and the effects of neuroprotective drugs.
Trends in pharmacological sciences 2003;24(4):184-91.
2003: Gassen M; Lamensdorf I; Armony T; Finberg J P M; Youdim M B H
Attenuation of methamphetamine induced dopaminergic neurotoxicity by flupirtine: microdialysis study on dopamine release and free radical generation.
Journal of neural transmission (Vienna, Austria : 1996) 2003;110(2):171-82.
2003: Naoi M; Maruyama W; Youdim M B H; Yu P; Boulton A A
Anti-apoptotic function of propargylamine inhibitors of type-B monoamine oxidase.
Inflammopharmacology 2003;11(2):175-81.
2003: Mandel Silvia; Reznichenko Lydia; Amit Tamar; Youdim Moussa B H
Green tea polyphenol (-)-epigallocatechin-3-gallate protects rat PC12 cells from apoptosis induced by serum withdrawal independent of P13-Akt pathway.
Neurotoxicity research 2003;5(6):419-24.
2003: Youdim M B H
What have we learnt from CDNA microarray gene expression studies about the role of iron in MPTP induced neurodegeneration and Parkinson's disease?
Journal of neural transmission. Supplementum 2003;(65):73-88.
2003: Mandel Silvia; Grünblatt Edna; Riederer Peter; Gerlach Manfred; Levites Yona; Youdim Moussa B H
Neuroprotective strategies in Parkinson's disease : an update on progress.
CNS drugs 2003;17(10):729-62.
2003: Gerlach Manfred; Double Kay L; Ben-Shachar Dorit; Zecca Luigi; Youdim Moussa B H; Riederer Peter
Neuromelanin and its interaction with iron as a potential risk factor for dopaminergic neurodegeneration underlying Parkinson's disease.
Neurotoxicity research 2003;5(1-2):35-44.
2003: Mandel Silvia; Grünblatt Edna; Riederer Peter; Youdim Moussa B H
Genes and oxidative stress in parkinsonism: cDNA microarray studies.
Advances in neurology 2003;91():123-32.
2002: Finberg John P M; Youdim Moussa B H
Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours.
Neuropharmacology 2002;43(7):1110-8.
2002: Sterling Jeffrey; Herzig Yaacov; Goren Tamar; Finkelstein Nina; Lerner David; Goldenberg Willy; Miskolczi Istvan; Molnar Sandor; Rantal Ferenc; Tamas Tivadar; Toth Gyorgy; Zagyva Adela; Zekany Andras; Finberg John; Lavian Gila; Gross Aviva; Friedman Rachel; Razin Michal; Huang Wei; Krais Boris; Chorev Michael; Youdim Moussa B; Weinstock Marta
Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease.
Journal of medicinal chemistry 2002;45(24):5260-79.
2002: Weinstock M; Gorodetsky E; Wang R H; Gross A; Weinreb O; Youdim M B H
Limited potentiation of blood pressure response to oral tyramine by brain-selective monoamine oxidase A-B inhibitor, TV-3326 in conscious rabbits.
Neuropharmacology 2002;43(6):999-1005.
2002: Mandel Silvia; Grünblatt Edna; Maor Gila; Youdim Moussa B H
Early and late gene changes in MPTP mice model of Parkinson's disease employing cDNA microarray.
Neurochemical research 2002;27(10):1231-43.
2002: Shoham S; Youdim M B H
The effects of iron deficiency and iron and zinc supplementation on rat hippocampus ferritin.
Journal of neural transmission (Vienna, Austria : 1996) 2002;109(10):1241-56.
2002: Yogev-Falach Merav; Amit Tamar; Bar-Am Orit; Weinstock Marta; Youdim Moussa B H
Involvement of MAP kinase in the regulation of amyloid precursor protein processing by novel cholinesterase inhibitors derived from rasagiline.
The FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2002;16(12):1674-6.
2002: Double K L; Ben-Shachar D; Youdim M B H; Zecca L; Riederer P; Gerlach M
Influence of neuromelanin on oxidative pathways within the human substantia nigra.
Neurotoxicology and teratology 2002;24(5):621-8.
2002: Naoi Makoto; Parvez Hasan; Maruyama Wakako; Collins Michel A; Youdim Moussa B H
Tribute to professor Toshiharu Nagatsu.
Neurotoxicology and teratology 2002;24(5):563-4.
2002: Akao Yukihiro; Maruyama Wakako; Shimizu Shigeomi; Yi Hong; Nakagawa Yoshihito; Shamoto-Nagai Masayo; Youdim Moussa B H; Tsujimoto Yoshihide; Naoi Makoto
Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan.
Journal of neurochemistry 2002;82(4):913-23.
2002: Avramovich Yael; Amit Tamar; Youdim Moussa B H
Non-steroidal anti-inflammatory drugs stimulate secretion of non-amyloidogenic precursor protein.
The Journal of biological chemistry 2002;277(35):31466-73.
2002: Levites Yona; Amit Tamar; Youdim Moussa B H; Mandel Silvia
Involvement of protein kinase C activation and cell survival/ cell cycle genes in green tea polyphenol (-)-epigallocatechin 3-gallate neuroprotective action.
The Journal of biological chemistry 2002;277(34):30574-80.
2002: Akao Yukihiro; Maruyama Wakako; Yi Hong; Shamoto-Nagai Masayo; Youdim Moussa B H; Naoi Makoto
An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells.
Neuroscience letters 2002;326(2):105-8.
2002: Youdim Moussa B H; Weinstock Marta
Novel neuroprotective anti-Alzheimer drugs with anti-depressant activity derived from the anti-Parkinson drug, rasagiline.
Mechanisms of ageing and development 2002;123(8):1081-6.
2002: Maruyama W; Takahashi T; Youdim M; Naoi M
The anti-Parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells.
Journal of neural transmission (Vienna, Austria : 1996) 2002;109(4):467-81.
2002: Youdim M B H; Tipton K F
Rat striatal monoamine oxidase-B inhibition by l-deprenyl and rasagiline: its relationship to 2-phenylethylamine-induced stereotypy and Parkinson's disease.
Parkinsonism & related disorders 2002;8(4):247-53.
2002: Weinstock Marta; Poltyrev Tatyana; Bejar Corina; Youdim Moussa B H
Effect of TV3326, a novel monoamine-oxidase cholinesterase inhibitor, in rat models of anxiety and depression.
Psychopharmacology 2002;160(3):318-24.
2002: Levites Yona; Youdim Moussa B H; Maor Gila; Mandel Silvia
Attenuation of 6-hydroxydopamine (6-OHDA)-induced nuclear factor-kappaB (NF-kappaB) activation and cell death by tea extracts in neuronal cultures.
Biochemical pharmacology 2002;63(1):21-9.
2001: Youdim M B; Weinstock M
Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate].
Cellular and molecular neurobiology 2001;21(6):555-73.
2001: Berg D; Gerlach M; Youdim M B; Double K L; Zecca L; Riederer P; Becker G
Brain iron pathways and their relevance to Parkinson's disease.
Journal of neurochemistry 2001;79(2):225-36.
2001: Levites Y; Weinreb O; Maor G; Youdim M B; Mandel S
Green tea polyphenol (-)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration.
Journal of neurochemistry 2001;78(5):1073-82.
2001: Maruyama W; Akao Y; Youdim M B; Davis B A; Naoi M
Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol.
Journal of neurochemistry 2001;78(4):727-35.
2001: Youdim M B
Deficiency and excess of iron in brain function and dysfunction.
Nutrition reviews 2001;59(8 Pt 2):S83-5; discussion S85-7.
2001: Grünblatt E; Mandel S; Maor G; Youdim M B
Gene expression analysis in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice model of Parkinson's disease using cDNA microarray: effect of R-apomorphine.
Journal of neurochemistry 2001;78(1):1-12.
2001: Youdim M B; Wadia A; Tatton W; Weinstock M
The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo.
Annals of the New York Academy of Sciences 2001;939():450-8.
2001: Maruyama W; Youdim M B; Naoi M
Antiapoptotic properties of rasagiline, N-propargylamine-1(R)-aminoindan, and its optical (S)-isomer, TV1022.
Annals of the New York Academy of Sciences 2001;939():320-9.
2001: Weinstock M; Kirschbaum-Slager N; Lazarovici P; Bejar C; Youdim M B; Shoham S
Neuroprotective effects of novel cholinesterase inhibitors derived from rasagiline as potential anti-Alzheimer drugs.
Annals of the New York Academy of Sciences 2001;939():148-61.
2001: Amit T; Amit T; Hochberg Z; Yogev-Falach M; Youdim M B; Youdim M B; Barkey R J
Shedding of growth hormone-binding protein is inhibited by hydroxamic acid-based protease inhibitors: proposed mechanism of activation of growth hormone-binding protein secretase.
The Journal of endocrinology 2001;169(2):397-407.
2001: Amit T; Amit T; Hochberg Z; Yogev-Falach M; Youdim M B; Youdim M B; Barkey R J
Shedding of growth hormone-binding protein is inhibited by hydroxamic acid-based protease inhibitors: proposed mechanism of activation of growth hormone-binding protein secretase.
The Journal of endocrinology 2001;169(2):397-407.
2001: Grünblatt E; Mandel S; Maor G; Youdim M B
Effects of R- and S-apomorphine on MPTP-induced nigro-striatal dopamine neuronal loss.
Journal of neurochemistry 2001;77(1):146-56.
2001: Youdim M B; Gross A; Finberg J P
Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B.
British journal of pharmacology 2001;132(2):500-6.
2001: Kupsch A; Sautter J; Götz M E; Breithaupt W; Schwarz J; Youdim M B; Riederer P; Gerlach M; Oertel W H
Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
Journal of neural transmission (Vienna, Austria : 1996) 2001;108(8-9):985-1009.
2001: Youdim M B; Grünblatt E; Levites-Royak Y; Mandel S
Drugs to prevent cell death in Parkinson's disease. Neuroprotection against oxidative stress and inflammatory gene expression.
Advances in neurology 2001;86():115-24.
2000: Maruyama W; Yamamoto T; Kitani K; Carrillo M C; Youdim M; Naoi M
Mechanism underlying anti-apoptotic activity of a (-)deprenyl-related propargylamine, rasagiline.
Mechanisms of ageing and development 2000;116(2-3):181-91.
2000: Youdim M B
Nutrient deprivation and brain function: iron.
Nutrition (Burbank, Los Angeles County, Calif.) 2000;16(7-8):504-8.
2000: Carrillo M C; Minami C; Kitani K; Maruyama W; Ohashi K; Yamamoto T; Naoi M; Kanai S; Youdim M B
Enhancing effect of rasagiline on superoxide dismutase and catalase activities in the dopaminergic system in the rat.
Life sciences 2000;67(5):577-85.
2000: Shoham S; Youdim M B
Iron involvement in neural damage and microgliosis in models of neurodegenerative diseases.
Cellular and molecular biology (Noisy-le-Grand, France) 2000;46(4):743-60.
2000: Youdim M B; Yehuda S
The neurochemical basis of cognitive deficits induced by brain iron deficiency: involvement of dopamine-opiate system.
Cellular and molecular biology (Noisy-le-Grand, France) 2000;46(3):491-500.
2000: Grünblatt E; Mandel S; Youdim M B
MPTP and 6-hydroxydopamine-induced neurodegeneration as models for Parkinson's disease: neuroprotective strategies.
Journal of neurology 2000;247 Suppl 2():II95-102.
2000: Amit T; Youdim M B; Hochberg Z
Clinical review 112: Does serum growth hormone (GH) binding protein reflect human GH receptor function?
The Journal of clinical endocrinology and metabolism 2000;85(3):927-32.
2000: Silver H; Youdim M B
MAO-A and MAO-B activities in rat striatum, frontal cortex and liver are unaltered after long-term treatment with fluvoxamine and desipramine.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 2000;10(2):125-8.
2000: Foley P; Gerlach M; Youdim M B; Riederer P
MAO-B inhibitors: multiple roles in the therapy of neurodegenerative disorders?
Parkinsonism & related disorders 2000;6(1):25-47.
2000: Gerlach M; Double K L; Youdim M B; Riederer P
Strategies for the protection of dopaminergic neurons against neurotoxicity.
Neurotoxicity research 2000;2(2-3):99-114.
2000: Youdim M B
Iron deficiency effects on brain function.
Public health reviews 2000;28(1-4):83-8.
2000: Double K L; Gerlach M; Youdim M B; Riederer P
Impaired iron homeostasis in Parkinson's disease.
Journal of neural transmission. Supplementum 2000;(60):37-58.
2000: Maruyama W; Akao Y; Youdim M B; Naoi M
Neurotoxins induce apoptosis in dopamine neurons: protection by N-propargylamine-1(R)- and (S)-aminoindan, rasagiline and TV1022.
Journal of neural transmission. Supplementum 2000;(60):171-86.
2000: Weinstock M; Bejar C; Wang R H; Poltyrev T; Gross A; Finberg J P; Youdim M B
TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer's disease.
Journal of neural transmission. Supplementum 2000;(60):157-69.
2000: Mandel S; Grünblatt E; Youdim M
cDNA microarray to study gene expression of dopaminergic neurodegeneration and neuroprotection in MPTP and 6-hydroxydopamine models: implications for idiopathic Parkinson's disease.
Journal of neural transmission. Supplementum 2000;(60):117-24.
2000: Youdim M B; Gassen M; Gross A; Mandel S; Grünblatt E
Iron chelating, antioxidant and cytoprotective properties of dopamine receptor agonist; apomorphine.
Journal of neural transmission. Supplementum 2000;(58):83-96.
2000: Naoi M; Maruyama W; Yagi K; Youdim M
Anti-apoptotic function of L-(-)deprenyl (Selegiline) and related compounds.
Neurobiology (Budapest, Hungary) 2000;8(1):69-80.
2000: Grünblatt E; Mandel S; Youdim M B
Neuroprotective strategies in Parkinson's disease using the models of 6-hydroxydopamine and MPTP.
Annals of the New York Academy of Sciences 2000;899():262-73.
1999: Grünblatt E; Mandel S; Berkuzki T; Youdim M B
Apomorphine protects against MPTP-induced neurotoxicity in mice.
Movement disorders : official journal of the Movement Disorder Society 1999;14(4):612-8.
1999: Amit T; Bar-Am O; Dastot F; Youdim M B; Amselem S; Hochberg Z
The human growth hormone (GH) receptor and its truncated isoform: sulfhydryl group inactivation in the study of receptor internalization and GH-binding protein generation.
Endocrinology 1999;140(1):266-72.
1999: Slikkker W; Youdim M; Palmer G C; Hall E; Williams C; Trembly B
The future of neuroprotection.
Annals of the New York Academy of Sciences 1999;890():529-33.
1999: Youdim M B; Grünblatt E; Mandel S
The pivotal role of iron in NF-kappa B activation and nigrostriatal dopaminergic neurodegeneration. Prospects for neuroprotection in Parkinson's disease with iron chelators.
Annals of the New York Academy of Sciences 1999;890():7-25.
1999: Sian J; Gerlach M; Youdim M B; Riederer P
Parkinson's disease: a major hypokinetic basal ganglia disorder.
Journal of neural transmission (Vienna, Austria : 1996) 1999;106(5-6):443-76.
1999: Finberg J P; Lamensdorf I; Weinstock M; Schwartz M; Youdim M B
Pharmacology of rasagiline (N-propargyl-1R-aminoindan).
Advances in neurology 1999;80():495-9.
1999: Gassen M; Gross A; Youdim M B
Apomorphine, a dopamine receptor agonist with remarkable antioxidant and cytoprotective properties.
Advances in neurology 1999;80():297-302.
1999: Gassen M; Youdim M B
Free radical scavengers: chemical concepts and clinical relevance.
Journal of neural transmission. Supplementum 1999;56():193-210.
1999: Grünblatt E; Mandel S; Gassen M; Youdim M B
Potent neuroprotective and antioxidant activity of apomorphine in MPTP and 6-hydroxydopamine induced neurotoxicity.
Journal of neural transmission. Supplementum 1999;55():57-70.
1998: Gassen M; Pergande G; Youdim M B
Antioxidant properties of the triaminopyridine, flupirtine.
Biochemical pharmacology 1998;56(10):1323-9.
1998: Gassen M; Gross A; Youdim M B
Apomorphine enantiomers protect cultured pheochromocytoma (PC12) cells from oxidative stress induced by H2O2 and 6-hydroxydopamine.
Movement disorders : official journal of the Movement Disorder Society 1998;13(4):661-7.
1998: Glinka Y; Tipton K F; Youdim M B
Mechanism of inhibition of mitochondrial respiratory complex I by 6-hydroxydopamine and its prevention by desferrioxamine.
European journal of pharmacology 1998;351(1):121-9.
1998: Gassen M; Gross A; Youdim M B
Apomorphine enantiomers protect cultured pheochromocytoma (PC12) cells from oxidative stress induced by H2O2 and 6-hydroxydopamine.
Movement disorders : official journal of the Movement Disorder Society 1998;13(2):242-8.
1998: Sterling J; Veinberg A; Lerner D; Goldenberg W; Levy R; Youdim M; Finberg J
(R)(+)-N-propargyl-1-aminoindan (rasagiline) and derivatives: highly selective and potent inhibitors of monoamine oxidase B.
Journal of neural transmission. Supplementum 1998;52():301-5.
1998: Götz M E; Breithaupt W; Sautter J; Kupsch A; Schwarz J; Oertel W H; Youdim M B; Riederer P; Gerlach M
Chronic TVP-1012 (rasagiline) dose--activity response of monoamine oxidases A and B in the brain of the common marmoset.
Journal of neural transmission. Supplementum 1998;52():271-8.
1998: Hocherman S; Levin G; Giladi N; Youdim M B
Deprenyl monotherapy improves visuo-motor control in early parkinsonism.
Journal of neural transmission. Supplementum 1998;52():63-9.
1998: Gassen M; Pinchasi B; Youdim M B
Apomorphine is a potent radical scavenger and protects cultured pheochromocytoma cells from 6-OHDA and H2O2-induced cell death.
Advances in pharmacology (San Diego, Calif.) 1998;42():320-4.
1997: Amit T; Bergman T; Dastot F; Youdim M B; Amselem S; Hochberg Z
A membrane-fixed, truncated isoform of the human growth hormone receptor.
The Journal of clinical endocrinology and metabolism 1997;82(11):3813-7.
1997: Gassen M; Youdim M B
The potential role of iron chelators in the treatment of Parkinson's disease and related neurological disorders.
Pharmacology & toxicology 1997;80(4):159-66.
1997: Gerlach M; Double K; Riederer P; Hirsch E; Jellinger K; Jenner P; Trautwein A; Youdim M B
Iron in the Parkinsonian substantia nigra.
Movement disorders : official journal of the Movement Disorder Society 1997;12(2):258-60.
1997: Youdim M B; Riederer P
Understanding Parkinson's disease.
Scientific American 1997;276(1):52-9.
1997: Glinka Y; Gassen M; Youdim M B
Mechanism of 6-hydroxydopamine neurotoxicity.
Journal of neural transmission. Supplementum 1997;50():55-66.
1996: Gerlach M; Youdim M B; Riederer P
Pharmacology of selegiline.
Neurology 1996;47(6 Suppl 3):S137-45.
1996: Pollard H B; Kuijpers G A; Adeyemo O M; Youdim M B; Goping G
The MPTP-induced parkinsonian syndrome in the goldfish is associated with major cell destruction in the forebrain and subtle changes in the optic tectum.
Experimental neurology 1996;142(1):170-8.
1996: Lamensdorf I; Youdim M B; Finberg J P
Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo.
Journal of neurochemistry 1996;67(4):1532-9.
1996: Amit T; Bick T; Youdim M B; Hochberg Z
In search of the cellular site of growth hormone (GH)-binding protein cleavage from the rabbit GH receptor.
Endocrinology 1996;137(9):3986-91.
1996: Bick T; Amit T; Mansur M; Bar-Am O; Youdim M B; Hochberg Z
Regulation of cellular rabbit growth hormone (GH) receptor and GH-binding protein generation in vitro.
Endocrinology 1996;137(9):3977-85.
1996: Goldstein D; Felzen B; Youdim M; Lotan R; Binah O
Experimental iron deficiency in rats: mechanical and electrophysiological alterations in the cardiac muscle.
Clinical science (London, England : 1979) 1996;91(2):233-9.
1996: Linert W; Herlinger E; Jameson R F; Kienzl E; Jellinger K; Youdim M B
Dopamine, 6-hydroxydopamine, iron, and dioxygen--their mutual interactions and possible implication in the development of Parkinson's disease.
Biochimica et biophysica acta 1996;1316(3):160-8.
1996: Gassen M; Glinka Y; Pinchasi B; Youdim M B
Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction.
European journal of pharmacology 1996;308(2):219-25.
1996: Glinka Y; Tipton K F; Youdim M B
Nature of inhibition of mitochondrial respiratory complex I by 6-Hydroxydopamine.
Journal of neurochemistry 1996;66(5):2004-10.
1996: Finberg J P; Lamensdorf I; Commissiong J W; Youdim M B
Pharmacology and neuroprotective properties of rasagiline.
Journal of neural transmission. Supplementum 1996;48():95-101.
1996: Gerlach M; Desser H; Youdim M B; Riederer P
New horizons in molecular mechanisms underlying Parkinson's disease and in our understanding of the neuroprotective effects of selegiline.
Journal of neural transmission. Supplementum 1996;48():7-21.
1996: Gerlach M; Riederer P; Youdim M B
Molecular mechanisms for neurodegeneration. Synergism between reactive oxygen species, calcium, and excitotoxic amino acids.
Advances in neurology 1996;69():177-94.
1995: Gerlach M; Trautwein A X; Zecca L; Youdim M B; Riederer P
Mössbauer spectroscopic studies of purified human neuromelanin isolated from the substantia nigra.
Journal of neurochemistry 1995;65(2):923-6.
1995: Sieradzan K; Channon S; Ramponi C; Stern G M; Lees A J; Youdim M B
The therapeutic potential of moclobemide, a reversible selective monoamine oxidase A inhibitor in Parkinson's disease.
Journal of clinical psychopharmacology 1995;15(4 Suppl 2):51S-59S.
1995: Gerlach M; Riederer P; Youdim M B
Neuroprotective therapeutic strategies. Comparison of experimental and clinical results.
Biochemical pharmacology 1995;50(1):1-16.
1995: Glinka Y Y; Youdim M B
Inhibition of mitochondrial complexes I and IV by 6-hydroxydopamine.
European journal of pharmacology 1995;292(3-4):329-32.
1995: Jellinger K; Linert L; Kienzl E; Herlinger E; Youdim M B
Chemical evidence for 6-hydroxydopamine to be an endogenous toxic factor in the pathogenesis of Parkinson's disease.
Journal of neural transmission. Supplementum 1995;46():297-314.
1995: Gsell W; Reichert N; Youdim M B; Riederer P
Interaction of neuroprotective substances with human brain superoxide dismutase. An in vitro study.
Journal of neural transmission. Supplementum 1995;45():271-9.
1995: Youdim M B
The advent of selective monoamine oxidase A inhibitor antidepressants devoid of the cheese reaction.
Acta psychiatrica Scandinavica. Supplementum 1995;386():5-7.
1995: Coleman R; Tanne Z; Nahir M; Shomrat D; Miller-Lotan R; Youdim M B
Ultrastructural changes in mitochondria of the adrenal cortex of iron-deficient rats.
Acta anatomica 1995;152(1):33-40.
1994: Lange K W; Riederer P; Youdim M B
Biochemical actions of l-deprenyl (selegiline).
Clinical pharmacology and therapeutics 1994;56(6 Pt 2):734-41.
1994: Youdim M B; Finberg J P
Pharmacological actions of l-deprenyl (selegiline) and other selective monoamine oxidase B inhibitors.
Clinical pharmacology and therapeutics 1994;56(6 Pt 2):725-33.
1994: Goldberg S R; Yasar S; Bergman J; Youdim M B
Introduction: examination of clinical and preclinical pharmacologic data relating to abuse liability of l-deprenyl (selegiline).
Clinical pharmacology and therapeutics 1994;56(6 Pt 2):721-4.
1994: Youdim M B; Lavie L; Riederer P
Oxygen free radicals and neurodegeneration in Parkinson's disease: a role for nitric oxide.
Annals of the New York Academy of Sciences 1994;738():64-8.
1994: Youdim M B
Parkinson's disease and milacemide.
Movement disorders : official journal of the Movement Disorder Society 1994;9(5):585-6.
1994: Gerlach M; Ben-Shachar D; Riederer P; Youdim M B
Altered brain metabolism of iron as a cause of neurodegenerative diseases?
Journal of neurochemistry 1994;63(3):793-807.
1994: Tanne Z; Coleman R; Nahir M; Shomrat D; Finberg J P; Youdim M B
Ultrastructural and cytochemical changes in the heart of iron-deficient rats.
Biochemical pharmacology 1994;47(10):1759-66.
1994: Hochberg Z; Youdim M B; Amit T
A mathematical model for appraisal of the impact of GH binding protein on GH receptor binding.
Growth regulation 1994;4(1):8-13.
1994: Janetzky B; Hauck S; Youdim M B; Riederer P; Jellinger K; Pantucek F; Zöchling R; Boissl K W; Reichmann H
Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's disease.
Neuroscience letters 1994;169(1-2):126-8.
1994: Ben-Shachar D; Livne E; Spanier I; Leenders K L; Youdim M B
Typical and atypical neuroleptics induce alteration in blood-brain barrier and brain 59FeCl3 uptake.
Journal of neurochemistry 1994;62(3):1112-8.
1994: O'Brien E M; Tipton K F; McCrodden J M; Youdim M B
The interactions of milacemide with monoamine oxidase.
Biochemical pharmacology 1994;47(4):617-23.
1994: Götz M E; Künig G; Riederer P; Youdim M B
Oxidative stress: free radical production in neural degeneration.
Pharmacology & therapeutics 1994;63(1):37-122.
1994: Gerlach M; Youdim M B; Riederer P
Is selegiline neuroprotective in Parkinson's disease?
Journal of neural transmission. Supplementum 1994;41():177-88.
1994: Lavian G; Finberg J P; Youdim M B
Comparison of the effect of reversible and irreversible MAO inhibitors on renal nerve activity in the anesthetized rat.
Journal of neural transmission. Supplementum 1994;41():107-13.
1994: Leenders K L; Antonini A; Schwarzbach R; Smith-Jones P; Reist H; Ben-Shachar D; Youdim M; Henn V
Blood to brain iron uptake in one rhesus monkey using [Fe-52]-citrate and positron emission tomography (PET): influence of haloperidol.
Journal of neural transmission. Supplementum 1994;43():123-32.
1994: Youdim M B; Ben-Shachar D; Riederer P
The enigma of neuromelanin in Parkinson's disease substantia nigra.
Journal of neural transmission. Supplementum 1994;43():113-22.
1994: Youdim M B; Lavie L
Selective MAO-A and B inhibitors, radical scavengers and nitric oxide synthase inhibitors in Parkinson's disease.
Life sciences 1994;55(25-26):2077-82.
1993: Hochberg Z; Phillip M; Youdim M B; Amit T
Regulation of the growth hormone (GH) receptor and GH-binding protein by GH pulsatility.
Metabolism: clinical and experimental 1993;42(12):1617-23.
1993: Yadid G; Maor G; Youdim M B; Silberman M; Zinder O
Autoradiographic localization of strychnine-sensitive glycine receptor in bovine adrenal medulla.
Neurochemical research 1993;18(10):1051-5.
1993: Paul I A; Basile A S; Rojas E; Youdim M B; De Costa B; Skolnick P; Pollard H B; Kuijpers G A
Sigma receptors modulate nicotinic receptor function in adrenal chromaffin cells.
The FASEB journal : official publication of the Federation of American Societies for Experimental Biology 1993;7(12):1171-8.
1993: Ben-Shachar D; Livne E; Spanier I; Zuk R; Youdim M B
Iron modulates neuroleptic-induced effects related to the dopaminergic system.
Israel journal of medical sciences 1993;29(9):587-92.
1993: Adeyemo O M; Youdim M B; Markey S P; Markey C J; Pollard H B
L-deprenyl confers specific protection against MPTP-induced Parkinson's disease-like movement disorder in the goldfish.
European journal of pharmacology 1993;240(2-3):185-93.
1993: Amit T; Hartmann K; Shoshany G; Baruch Y; Youdim M B; Hochberg Z
The turnover of growth hormone (GH)-binding protein and GH receptor in rabbit and rat.
Molecular and cellular endocrinology 1993;94(2):149-54.
1993: Yadid G; Youdim M B; Zinder O
Uptake and receptor sites for glycine in isolated bovine adrenal medulla chromaffin cells.
Neuroscience 1993;55(4):1147-52.
1993: Pollard H B; Adeyemo M; Dhariwal K; Levine M; Caohuy H; Markey S; Markey C J; Youdim M B
The goldfish as a drug discovery vehicle for Parkinson's disease and other neurodegenerative disorders.
Annals of the New York Academy of Sciences 1993;679():317-20.
1993: Jellinger K; Kienzl E; Rumpelmair G; Riederer P; Stachelberger H; Ben-Shachar D; Youdim M B
Neuromelanin and nigrostriatal dopamine neuron degeneration.
Journal of neurochemistry 1993;60(5):1976-7.
1993: Ben-Shachar D; Youdim M B
Iron, melanin and dopamine interaction: relevance to Parkinson's disease.
Progress in neuro-psychopharmacology & biological psychiatry 1993;17(1):139-50.
1993: Jellinger K A; Kienzl E; Rumpelmaier G; Paulus W; Riederer P; Stachelberger H; Youdim M B; Ben-Shachar D
Iron and ferritin in substantia nigra in Parkinson's disease.
Advances in neurology 1993;60():267-72.
1993: Youdim M B; Ben-Shachar D; Riederer P
The possible role of iron in the etiopathology of Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 1993;8(1):1-12.
1993: Youdim M B; Riederer P
Dopamine metabolism and neurotransmission in primate brain in relationship to monoamine oxidase A and B inhibition.
Journal of neural transmission. General section 1993;91(2-3):181-95.
1993: Youdim M B; Ben-Shachar D; Eshel G; Finberg J P; Riederer P
The neurotoxicity of iron and nitric oxide. Relevance to the etiology of Parkinson's disease.
Advances in neurology 1993;60():259-66.
1993: Lavian G; Finberg J P; Youdim M B
The advent of a new generation of monoamine oxidase inhibitor antidepressants: pharmacologic studies with moclobemide and brofaromine.
Clinical neuropharmacology 1993;16 Suppl 2():S1-7.
1993: Youdim M B; Riederer P
The relevance of glial monoamine oxidase-B and polyamines to the action of selegiline in Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 1993;8 Suppl 1():S8-13.
1993: Youdim M B; Riederer P
The role of iron in senescence of dopaminergic neurons in Parkinson's disease.
Journal of neural transmission. Supplementum 1993;40():57-67.
1993: Riederer P; Lange K W; Youdim M B
Recent advances in pharmacological therapy of Parkinson's disease.
Advances in neurology 1993;60():626-35.
1993: Baruch Y; Amit T; Hertz P; Enat R; Shoshany G; Youdim M B; Hochberg Z
Growth hormone-binding protein in partially hepatectomized rats.
Hormone research 1993;40(5-6):173-7.
1992: Blumenfeld Z; Barkey R J; Youdim M B; Brandes J M; Amit T
Growth hormone (GH)-binding protein regulation by estrogen, progesterone, and gonadotropins in human: the effect of ovulation induction with menopausal gonadotropins, GH, and gestation.
The Journal of clinical endocrinology and metabolism 1992;75(5):1242-9.
1992: Yadid G; Youdim M B; Zinder O
Preferential release of epinephrine by glycine from adrenal chromaffin cells.
European journal of pharmacology 1992;221(2-3):389-91.
1992: Pollard H B; Dhariwal K; Adeyemo O M; Markey C J; Caohuy H; Levine M; Markey S; Youdim M B
A parkinsonian syndrome induced in the goldfish by the neurotoxin MPTP.
The FASEB journal : official publication of the Federation of American Societies for Experimental Biology 1992;6(12):3108-16.
1992: Jellinger K; Kienzl E; Rumpelmair G; Riederer P; Stachelberger H; Ben-Shachar D; Youdim M B
Iron-melanin complex in substantia nigra of parkinsonian brains: an x-ray microanalysis.
Journal of neurochemistry 1992;59(3):1168-71.
1992: Amit T; Barkey R J; Youdim M B; Hochberg Z
Modulation of human growth hormone binding to somatogenic and lactogenic receptors by monoclonal antibodies to human growth hormone.
Cellular signalling 1992;4(5):553-8.
1992: Amit T; Barkey R J; Youdim M B; Hochberg Z
Effect of human growth hormone (GH)-binding protein in human serum on GH binding to rabbit liver membranes.
Metabolism: clinical and experimental 1992;41(7):732-7.
1992: Gerlach M; Riederer P; Youdim M B
The molecular pharmacology of L-deprenyl.
European journal of pharmacology 1992;226(2):97-108.
1992: Youdim M B; Dhariwal K; Levine M; Markey C J; Markey S; Caohuy H; Adeyemo O M; Pollard H B
MPTP-induced "parkinsonism" in the goldfish.
Neurochemistry international 1992;20 Suppl():275S-278S.
1992: Hochberg Z; Hertz P; Colin V; Ish-Shalom S; Yeshurun D; Youdim M B; Amit T
The distal axis of growth hormone (GH) in nutritional disorders: GH-binding protein, insulin-like growth factor-I (IGF-I), and IGF-I receptors in obesity and anorexia nervosa.
Metabolism: clinical and experimental 1992;41(1):106-12.
1992: Ben-Shachar D; Eshel G; Riederer P; Youdim M B
Role of iron and iron chelation in dopaminergic-induced neurodegeneration: implication for Parkinson's disease.
Annals of neurology 1992;32 Suppl():S105-10.
1992: Riederer P; Dirr A; Goetz M; Sofic E; Jellinger K; Youdim M B
Distribution of iron in different brain regions and subcellular compartments in Parkinson's disease.
Annals of neurology 1992;32 Suppl():S101-4.
1992: Lange K W; Youdim M B; Riederer P
Neurotoxicity and neuroprotection in Parkinson's disease.
Journal of neural transmission. Supplementum 1992;38():27-44.
1992: Amit T; Ish-Shalom S; Glaser B; Youdim M B; Hochberg Z
Growth-hormone-binding protein in patients with acromegaly.
Hormone research 1992;37(6):205-11.
1991: Ben-Shachar D; Youdim M B
Intranigral iron injection induces behavioral and biochemical "parkinsonism" in rats.
Journal of neurochemistry 1991;57(6):2133-5.
1991: Gerlach M; Riederer P; Przuntek H; Youdim M B
MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease.
European journal of pharmacology 1991;208(4):273-86.
1991: Ben-Shachar D; Riederer P; Youdim M B
Iron-melanin interaction and lipid peroxidation: implications for Parkinson's disease.
Journal of neurochemistry 1991;57(5):1609-14.
1991: Yadid G; Zinder O; Youdim M B
Effects of the glycine prodrug milacemide (2-N-pentylaminoacetamide) on catecholamine secretion from isolated adrenal medulla chromaffin cells.
British journal of pharmacology 1991;104(3):760-4.
1991: Baruch Y; Amit T; Hertz P; Enat R; Youdim M B; Hochberg Z
Decreased serum growth hormone-binding protein in patients with liver cirrhosis.
The Journal of clinical endocrinology and metabolism 1991;73(4):777-80.
1991: Ben-Shachar D; Pinhassi B; Youdim M B
Prevention of neuroleptic-induced dopamine D2 receptor supersensitivity by chronic iron salt treatment.
European journal of pharmacology 1991;202(2):177-83.
1991: Amit T; Hertz P; Ish-Shalom S; Lotan R; Luboshitzki R; Youdim M B; Hochberg Z
Effects of hypo or hyper-thyroidism on growth hormone-binding protein.
Clinical endocrinology 1991;35(2):159-62.
1991: Hochberg Z; Barkey R J; Even L; Peleg I; Youdim M B; Amit T
The effect of human growth hormone therapy on GH binding protein in GH-deficient children.
Acta endocrinologica 1991;125(1):23-7.
1991: Ben-Shachar D; Eshel G; Finberg J P; Youdim M B
The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons.
Journal of neurochemistry 1991;56(4):1441-4.
1991: Yehuda S; Mei-Tal R; Youdim M
The effects of iron deficiency and electric shock on learning in rats.
The International journal of neuroscience 1991;57(1-2):81-94.
1991: Sofic E; Paulus W; Jellinger K; Riederer P; Youdim M B
Selective increase of iron in substantia nigra zona compacta of parkinsonian brains.
Journal of neurochemistry 1991;56(3):978-82.
1991: Youdim M B
Modulation of monoamine oxidase a activity in PC12 cells by steroids.
European journal of pharmacology 1991;192(1):201-2.
1991: Youdim M B; Finberg J P
New directions in monoamine oxidase A and B selective inhibitors and substrates.
Biochemical pharmacology 1991;41(2):155-62.
1991: Youdim M B
PC12 cells as a window for the differentiation of neural crest into adrenergic nerve ending and adrenal medulla.
Journal of neural transmission. Supplementum 1991;34():61-7.
1991: Hochberg Z; Amit T; Youdim M B
The growth hormone binding protein as a paradigm of the erythropoietin superfamily of receptors.
Cellular signalling 1991;3(2):85-91.
1991: Youdim M B; Ben-Shachar D; Riederer P
Iron in brain function and dysfunction with emphasis on Parkinson's disease.
European neurology 1991;31 Suppl 1():34-40.
1990: Melamed E; Rosenthal J; Youdim M B
Immunity of fetal mice to prenatal administration of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Journal of neurochemistry 1990;55(4):1427-31.
1990: Amit T; Barkey R J; Youdim M B; Hochberg Z
A new and convenient assay of growth hormone-binding protein activity in human serum.
The Journal of clinical endocrinology and metabolism 1990;71(2):474-80.
1990: Paul I A; Kuypers G; Youdim M; Skolnick P
Polyamines non-competitively inhibit [3H]3-PPP binding to sigma receptors.
European journal of pharmacology 1990;184(1):203-4.
1990: Amit T; Barkey R J; Bick T; Hertz P; Youdim M B; Hockberg Z
Identification of growth hormone binding protein in rat serum.
Molecular and cellular endocrinology 1990;70(2):197-202.
1990: Bick T; Amit T; Barkey R J; Hertz P; Youdim M B; Hochberg Z
The interrelationship of growth hormone (GH), liver membrane GH receptor, serum GH-binding protein activity, and insulin-like growth factor I in the male rat.
Endocrinology 1990;126(4):1914-20.
1990: Mor L; Bomzon A; Frenkel R; Youdim M B
Angiotensin-converting enzyme activity in the isolated perfused guinea pig lung.
Journal of pharmacological methods 1990;23(2):141-53.
1990: Ben-Shachar D; Youdim M B
Neuroleptic-induced supersensitivity and brain iron: I. Iron deficiency and neuroleptic-induced dopamine D2 receptor supersensitivity.
Journal of neurochemistry 1990;54(4):1136-41.
1990: Youdim M B
Monoamine oxidase (MAO)-A but not MAO-B inhibitors potentiate tyramine-induced catecholamine release from PC12 cells.
Journal of neurochemistry 1990;54(2):411-4.
1990: Yadid G; Youdim M B; Zinder O
High-affinity strychnine binding to adrenal medulla chromaffin cell membranes.
European journal of pharmacology 1990;175(3):365-6.
1990: Youdim M B
Inhibitors of dopamine inactivating systems as antiparkinson drugs.
Advances in neurology 1990;53():483-8.
1990: Hochberg Z; Bick T; Amit T; Barkey R J; Youdim M B
Regulation of growth hormone receptor turnover by growth hormone.
Acta paediatrica Scandinavica. Supplement 1990;367():148-52.
1990: Ben-Shachar D; Youdim M B
Selectivity of melaninized nigra-striatal dopamine neurons to degeneration in Parkinson's disease may depend on iron-melanin interaction.
Journal of neural transmission. Supplementum 1990;29():251-8.
1990: Riederer P; Konradi C; Youdim M B
The role of MAO in dopaminergic transmission.
Advances in neurology 1990;53():149-53.
1990: Youdim M B; Ben-Shachar D; Riederer P
The role of monoamine oxidase, iron-melanin interaction, and intracellular calcium in Parkinson's disease.
Journal of neural transmission. Supplementum 1990;32():239-48.
1990: Jellinger K; Paulus W; Grundke-Iqbal I; Riederer P; Youdim M B
Brain iron and ferritin in Parkinson's and Alzheimer's diseases.
Journal of neural transmission. Parkinson's disease and dementia section 1990;2(4):327-40.
1990: Youdim M B; Ben-Shachar D; Yehuda S; Riederer P
The role of iron in the basal ganglion.
Advances in neurology 1990;53():155-62.
1989: Janssens de Varebeke P; Pauwels G; Buyse C; David-Remacle M; De Mey J; Roba J; Youdim M B
The novel neuropsychotropic agent milacemide is a specific enzyme-activated inhibitor of brain monoamine oxidase B.
Journal of neurochemistry 1989;53(4):1109-16.
1989: Youdim M B; Ben-Shachar D; Yehuda S
Putative biological mechanisms of the effect of iron deficiency on brain biochemistry and behavior.
The American journal of clinical nutrition 1989;50(3 Suppl):607-15; discussion 615-7.
1989: Bick T; Youdim M B; Hochberg Z
The dynamics of somatogenic and lactogenic growth hormone binding: internalization to Golgi fractions in the male rat.
Endocrinology 1989;125(3):1718-22.
1989: Bick T; Youdim M B; Hochberg Z
Adaptation of liver membrane somatogenic and lactogenic growth hormone (GH) binding to the spontaneous pulsation of GH secretion in the male rat.
Endocrinology 1989;125(3):1711-7.
1989: Yehuda S; Youdim M B
Brain iron: a lesson from animal models.
The American journal of clinical nutrition 1989;50(3 Suppl):618-25; discussion 625-9.
1989: Youdim M B; Banerjee D K; Kelner K; Offutt L; Pollard H B
Steroid regulation of monoamine oxidase activity in the adrenal medulla.
The FASEB journal : official publication of the Federation of American Societies for Experimental Biology 1989;3(6):1753-9.
1989: Kraiem Z; Sadeh O; Youdim M B
Monoamine oxidase activity and triiodothyronine biosynthesis in human cultured thyroid cells.
British journal of pharmacology 1989;96(2):465-9.
1989: Riederer P; Sofic E; Rausch W D; Schmidt B; Reynolds G P; Jellinger K; Youdim M B
Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains.
Journal of neurochemistry 1989;52(2):515-20.
1989: Youdim M B; Ben-Shachar D; Riederer P
Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration?
Acta neurologica Scandinavica. Supplementum 1989;126():47-54.
1989: Riederer P; Konradi C; Hebenstreit G; Youdim M B
Neurochemical perspectives to the function of monoamine oxidase.
Acta neurologica Scandinavica. Supplementum 1989;126():41-5.
1989: Youdim M B; Barkey R J; Amit T; Guy J
Anti-idiotypic antibodies as probes of prolactin receptor.
Methods in enzymology 1989;178():308-20.
1989: Youdim M B
Brain monoamine oxidase (MAO) B: a unique neurotoxin and neurotransmitter producing enzyme.
Progress in neuro-psychopharmacology & biological psychiatry 1989;13(3-4):363-71.
1988: Youdim M B; Riederer P
Monoamine oxidase B; a misunderstood and misjudged enzyme.
Pharmacological research communications 1988;20 Suppl 4():9-14.
1988: Okun F; Weizman R; Katz Y; Bomzon A; Youdim M B; Gavish M
Increase in central and peripheral benzodiazepine receptors following surgery.
Brain research 1988;458(1):31-6.
1988: Youdim M B; Kerem D; Duvdevani Y
The glycine-prodrug, milacemide, increases the seizure threshold due to hyperbaric oxygen; prevention by 1-deprenyl.
European journal of pharmacology 1988;150(3):381-4.
1988: Ben-Shachar D; Yehuda S; Finberg J P; Spanier I; Youdim M B
Selective alteration in blood-brain barrier and insulin transport in iron-deficient rats.
Journal of neurochemistry 1988;50(5):1434-7.
1988: Janssens de Varebeke P; Cavalier R; David-Remacle M; Youdim M B
Formation of the neurotransmitter glycine from the anticonvulsant milacemide is mediated by brain monoamine oxidase B.
Journal of neurochemistry 1988;50(4):1011-6.
1988: Youdim M B
Platelet monoamine oxidase B: use and misuse.
Experientia 1988;44(2):137-41.
1988: Youdim M B
Iron in the brain: implications for Parkinson's and Alzheimer's diseases.
The Mount Sinai journal of medicine, New York 1988;55(1):97-101.
1988: Sofic E; Riederer P; Heinsen H; Beckmann H; Reynolds G P; Hebenstreit G; Youdim M B
Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain.
Journal of neural transmission 1988;74(3):199-205.
1988: Finberg J P; Youdim M B
Potentiation of tyramine pressor responses in conscious rats by reversible inhibitors of monoamine oxidase.
Journal of neural transmission. Supplementum 1988;26():11-6.
1987: Gavish M; Weizman A; Youdim M B; Okun F
Regulation of central and peripheral benzodiazepine receptors in progesterone-treated rats.
Brain research 1987;409(2):386-90.
1987: Heal D J; Stoodley N; Elliott J M; Marsden C A; Bennett G W; Youdim M B
Behavioural and biochemical evidence for the release of noradrenaline in mouse brain by TRH and some of its biologically stable analogues.
Neuropharmacology 1987;26(4):313-22.
1987: Amit T; Barkey R J; Guy J; Youdim M B
Specific binding sites for prolactin and growth hormone in the adult rabbit lung.
Molecular and cellular endocrinology 1987;49(1):17-24.
1987: Youdim M B; Ben-Shachar D
Minimal brain damage induced by early iron deficiency: modified dopaminergic neurotransmission.
Israel journal of medical sciences 1987;23(1-2):19-25.
1987: Pick C G; Statter M; Ben Shachar D; Youdim M B; Yanai J
Normal zinc and iron concentrations in mice after early exposure to phenobarbital.
International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience 1987;5(5-6):391-8.
1987: Youdim M B; Finberg J P
Monoamine oxidase B inhibition and the "cheese effect".
Journal of neural transmission. Supplementum 1987;25():27-33.
1987: Youdim M B; Finberg J P
MAO type B inhibitors as adjunct to L-dopa therapy.
Advances in neurology 1987;45():127-36.
1987: Youdim M B; Tenne M
Assay and purification of liver monoamine oxidase.
Methods in enzymology 1987;142():617-27.
1987: Riederer P; Konradi C; Schay V; Kienzl E; Birkmayer G; Danielczyk W; Sofic E; Youdim M B
Localization of MAO-A and MAO-B in human brain: a step in understanding the therapeutic action of L-deprenyl.
Advances in neurology 1987;45():111-8.
1986: Youdim M B; Heldman E; Pollard H B; Fleming P; McHugh E
Contrasting monoamine oxidase activity and tyramine induced catecholamine release in PC12 and chromaffin cells.
Neuroscience 1986;19(4):1311-8.
1986: Tipton K F; McCrodden J M; Youdim M B
Oxidation and enzyme-activated irreversible inhibition of rat liver monoamine oxidase-B by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
The Biochemical journal 1986;240(2):379-83.
1986: Gavish M; Weizman A; Okun F; Youdim M B
Modulatory effects of thyroxine treatment on central and peripheral benzodiazepine receptors in the rat.
Journal of neurochemistry 1986;47(4):1106-10.
1986: Youdim M B; Feldman S C; Pappas G D; Pollard H B
Serotonin metabolism and the nature of monoamine oxidase in squid central nervous system.
Brain research 1986;381(2):300-4.
1986: Youdim M B; Sills M A; Heydorn W E; Creed G J; Jacobowitz D M
Iron deficiency alters discrete proteins in rat caudate nucleus and nucleus accumbens.
Journal of neurochemistry 1986;47(3):794-9.
1986: Gavish M; Okun F; Weizman A; Youdim M B
Modulation of peripheral benzodiazepine binding sites following chronic estradiol treatment.
European journal of pharmacology 1986;127(1-2):147-51.
1986: Riederer P; Youdim M B
Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl.
Journal of neurochemistry 1986;46(5):1359-65.
1986: Barkey R J; Amit T; Ben-Shachar D; Youdim M B
Characterization of the hepatic prolactin receptors induced by chronic iron deficiency and neuroleptics.
European journal of pharmacology 1986;122(2):259-67.
1986: Amit T; Barkey R J; Gavish M; Youdim M B
Antiidiotypic antibodies raised against anti-prolactin (PRL) antibodies recognize the PRL receptor.
Endocrinology 1986;118(2):835-43.
1986: Blinder B J; Goodman S; Youdim M B
Brain iron, dopamine receptor sensitivity, and tardive dyskinesia.
The American journal of psychiatry 1986;143(2):277-8.
1986: Youdim M B
Pharmacology of MAO B inhibitors: mode of action of (-)deprenyl in Parkinson's disease.
Journal of neural transmission. Supplementum 1986;22():91-105.
1986: Konradi C; Riederer P; Youdim M B
Hydrogen peroxide enhances the activity of monoamine oxidase type-B but not of type-A: a pilot study.
Journal of neural transmission. Supplementum 1986;22():61-73.
1986: Ben-Shachar D; Ashkenazi R; Youdim M B
Long-term consequence of early iron-deficiency on dopaminergic neurotransmission in rats.
International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience 1986;4(1):81-8.
1985: Melamed E; Youdim M B; Rosenthal J; Spanier I; Uzzan A; Globus M
In vivo effect of MPTP on monoamine oxidase activity in mouse striatum.
Brain research 1985;359(1-2):360-3.
1985: Youdim M B; Ashkenazi R
Serotonergic involvement in pharmacological action of the anxiolytic-sedatives thalidomide and supidimide.
European journal of pharmacology 1985;119(1-2):39-46.
1985: Melamed E; Youdim M B
Prevention of dopaminergic toxicity of MPTP in mice by phenylethylamine, a specific substrate of type B monoamine oxidase.
British journal of pharmacology 1985;86(3):529-31.
1985: Skolnick P; Weissman B A; Youdim M B
Monoaminergic involvement in the pharmacological actions of buspirone.
British journal of pharmacology 1985;86(3):637-44.
1985: Heikkila R E; Duvoisin R C; Finberg J P; Youdim M B
Prevention of MPTP-induced neurotoxicity by AGN-1133 and AGN-1135, selective inhibitors of monoamine oxidase-B.
European journal of pharmacology 1985;116(3):313-7.
1985: Ben-Shachar D; Finberg J P; Youdim M B
Effect of iron chelators on dopamine D2 receptors.
Journal of neurochemistry 1985;45(4):999-1005.
1985: Bomzon A; Blendis L M; Better O S; Yarhi D; Copel Y; Youdim M B
Modification of pulmonary metabolism of noradrenaline in experimental obstructive jaundice.
Biochemical pharmacology 1985;34(17):3049-54.
1985: Youdim M B; Yehuda S
Iron deficiency induces reversal of dopamine dependent circadian cycles: differential response to d-amphetamine and TRH.
Peptides 1985;6(5):851-5.
1985: Banerjee D K; Ornberg R L; Youdim M B; Heldman E; Pollard H B
Endothelial cells from bovine adrenal medulla develop capillary-like growth patterns in culture.
Proceedings of the National Academy of Sciences of the United States of America 1985;82(14):4702-6.
1985: Youdim M B
Oxidation by rat brain of N-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) coupled to tetrazolium nitro blue.
European journal of pharmacology 1985;113(2):283-6.
1985: Finberg J P; Youdim M B
Modification of blood pressure and nictitating membrane response to sympathetic amines by selective monoamine oxidase inhibitors, types A and B, in the cat.
British journal of pharmacology 1985;85(2):541-6.
1985: Tenne M; Finberg J P; Youdim M B; Ulitzur S
A new rapid and sensitive bioluminescence assay for monoamine oxidase activity.
Journal of neurochemistry 1985;44(5):1378-84.
1985: Tenne M; Youdim M B; Ulitzur S; Finberg J P
Deamination of aliphatic amines by monoamine oxidase A and B studied using a bioluminescence technique.
Journal of neurochemistry 1985;44(5):1373-7.
1985: Wolf W A; Youdim M B; Kuhn D M
Does brain 5-HIAA indicate serotonin release or monoamine oxidase activity?
European journal of pharmacology 1985;109(3):381-7.
1985: Barkey R J; Ben-Shachar D; Amit T; Youdim M B
Increased hepatic and reduced prostatic prolactin (PRL) binding in iron deficiency and during neuroleptic treatment: correlation with changes in serum PRL and testosterone.
European journal of pharmacology 1985;109(2):193-200.
1985: Amit T; Barkey R J; Gavish M; Youdim M B
Induction of prolactin receptors by prolactin in the rat lung and liver: demonstration of separate receptor and antibody entities.
Molecular and cellular endocrinology 1985;39(1):21-9.
1985: Kuhn D M; Wolf W A; Youdim M B
5-Hydroxytryptamine release in vivo from a cytoplasmic pool: studies on the 5-HT behavioural syndrome in reserpinized rats.
British journal of pharmacology 1985;84(1):121-9.
1985: Birkmayer W; Knoll J; Riederer P; Youdim M B; Hars V; Marton J
Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study.
Journal of neural transmission 1985;64(2):113-27.
1984: Yehuda S; Youdim M B
The increased opiate action of beta-endorphin in iron-deficient rats: the possible involvement of dopamine.
European journal of pharmacology 1984;104(3-4):245-51.
1984: Youdim M B; Banerjee D K; Pollard H B
Isolated chromaffin cells from adrenal medulla contain primarily monoamine oxidase B.
Science (New York, N.Y.) 1984;224(4649):619-21.
1984: Amit T; Barkey R J; Gavish M; Youdim M B
Induction of prolactin (PRL) receptors by PRL in the rat lung and liver. Demonstration and characterization of a soluble receptor.
Endocrinology 1984;114(2):545-52.
1984: Youdim M B; Ashkenazi R; Ben-Shachar D; Yehuda S
Modulation of dopamine receptor in the striatum by iron: behavioral and biochemical correlates.
Advances in neurology 1984;40():159-70.
1984: Youdim M B; Finberg J P; Wajsbort J
Monoamine oxidase type B inhibitors in the treatment of Parkinson's disease.
Progress in medicinal chemistry 1984;21():137-67.
1984: Wajsbort J; Youdim M B
A new selective suicide inhibitor of peripheral DOPA decarboxylase.
Advances in neurology 1984;40():251-8.
1983: Markel A; Brook J G; Levy Y; Aviram M; Youdim M B
Increased platelet adhesion and aggregation in hypertensive patients: effect of atenolol.
British journal of clinical pharmacology 1983;16(6):663-8.
1983: Hovevei-Sion D; Finberg J P; Bomzon A; Youdim M B
Effects of forskolin in rat vas deferens--evidence for facilitatory beta-adrenoceptors.
European journal of pharmacology 1983;95(3-4):295-9.
1983: Ashkenazi R; Finberg J P; Youdim M B
Effects of LM 5008, a selective inhibitor of 5-hydroxytryptamine uptake, on blood pressure and responses to sympathomimetic amines.
British journal of pharmacology 1983;79(4):915-22.
1983: Ashkenazi R; Finberg J P; Youdim M B
Behavioural hyperactivity in rats treated with selective monoamine oxidase inhibitors and LM 5008, a selective 5-hydroxytryptamine uptake blocker.
British journal of pharmacology 1983;79(3):765-70.
1983: Youdim M B
In vivo, noradrenaline is a substrate for rat brain monoamine oxidase A and B.
British journal of pharmacology 1983;79(2):477-80.
1983: Ben-Harari R R; Amit T; Youdim M B
Binding of oestradiol, progesterone and prolactin in rat lung.
The Journal of endocrinology 1983;97(2):301-10.
1983: Amit T; Barkey R J; Youdim M B
Effect of prolactin, testosterone and estrogen on prolactin binding in the rat testis, prostate, seminal vesicle and liver.
Molecular and cellular endocrinology 1983;30(2):179-87.
1983: Mendlewicz J; Youdim M B
L-Deprenil, a selective monoamine oxidase type B inhibitor, in the treatment of depression: a double blind evaluation.
The British journal of psychiatry : the journal of mental science 1983;142():508-11.
1983: Gavish M; Amit T; Barkey R J; Youdim M B
Characterization of CHAPS-solubilized prolactin receptors induced by estradiol in liver of male rats. Unmasking of cryptic sites by CHAPS.
FEBS letters 1983;154(1):81-6.
1983: Finberg J P; Youdim M B
Selective MAO A and B inhibitors: their mechanism of action and pharmacology.
Neuropharmacology 1983;22(3 Spec No):441-6.
1983: Holzbauer M; Youdim M B
Specific changes in type A and B monoamine oxidase activity in different tissues of hypophysectomized rats.
Biochemical pharmacology 1983;32(3):469-73.
1983: Ben-Harari R R; Youdim M B
The lung as an endocrine organ.
Biochemical pharmacology 1983;32(2):189-97.
1983: Hochberg Z; Amit T; Youdim M B; Bar-Maor J A
Prolactin binding by testes of unilaterally cryptorchid rats: the effect of hCG, testosterone, prolactin and orchiopexy.
Acta endocrinologica 1983;102(1):144-9.
1983: Birkmayer W; Knoll J; Riederer P; Youdim M B
(-)-Deprenyl leads to prolongation of L-dopa efficacy in Parkinson's disease.
Modern problems of pharmacopsychiatry 1983;19():170-6.
1983: Youdim M B; Finberg J P
Implications of MAO-A and MAO-B inhibition for antidepressant therapy.
Modern problems of pharmacopsychiatry 1983;19():63-74.
1983: Mishra R; Gillespie D D; Youdim M B; Sulser F
Effect of selective monoamine oxidase inhibition by clorgyline and deprenyl on the norepinephrine receptor-coupled adenylate cyclase system in rat cortex.
Psychopharmacology 1983;81(3):220-3.
1983: Youdim M B; Ben-Shachar D; Ashkenazi R; Yehuda S
Brain iron and dopamine receptor function.
Advances in biochemical psychopharmacology 1983;37():309-21.
1982: Fowler C J; Tipton K F; MacKay A V; Youdim M B
Human platelet monoamine oxidase--a useful enzyme in the study of psychiatric disorders?
Neuroscience 1982;7(7):1577-94.
1982: Ben-Harari R R; Peleg R; Youdim M B
Rate-limiting step in the metabolism of polar and non-polar monoamines in lung and liver.
British journal of pharmacology 1982;76(1):77-83.
1982: Tipton K F; McCrodden J M; Kalir A S; Youdim M B
Inhibition of rat liver monoamine oxidase by alpha-methyl- and N-propargyl-amine derivatives.
Biochemical pharmacology 1982;31(7):1251-5.
1982: Ashkenazi R; Ben-Shachar D; Youdim M B
Nutritional iron and dopamine binding sites in the rat brain.
Pharmacology, biochemistry, and behavior 1982;17 Suppl 1():43-7.
1982: Youdim M B; Ashkenazi R
Regulation of 5-HT catabolism.
Advances in biochemical psychopharmacology 1982;34():35-60.
1982: Birkmayer W; Riederer P; Youdim M B
(-)Deprenyl in the treatment of Parkinson's disease.
Clinical neuropharmacology 1982;5(2):195-230.
1981: Youdim M B; Hefez A; Oppenheim B
Human platelet function as a model for investigating the clinical efficacy of chlorpromazine.
British journal of clinical pharmacology 1981;12(4):535-42.
1981: Heal D J; Sabbagh A; Youdim M B; Green A R
Behavioural effects of central and peripheral injection of various analogues and metabolites of thyrotropin releasing hormone (TRH).
Neuropharmacology 1981;20(10):947-57.
1981: Youdim M B; Yehuda S; Ben-Uriah Y
Iron deficiency-induced circadian rhythm reversal of dopaminergic-mediated behaviours and thermoregulation in rats.
European journal of pharmacology 1981;74(4):295-301.
1981: Ben-Harari R R; Lanir A; Youdim M B
Effect of hyperoxia on uptake and metabolism of 5-hydroxytryptamine and beta-phenylethylamine in rat lung: a sex difference.
British journal of pharmacology 1981;73(2):461-6.
1981: Kalir A; Sabbagh A; Youdim M B
Selective acetylenic 'suicide' and reversible inhibitors of monoamine oxidase types A and B.
British journal of pharmacology 1981;73(1):55-64.
1981: Finberg J P; Tenne M; Youdim M B
Tyramine antagonistic properties of AGN 1135, an irreversible inhibitor of monoamine oxidase type B.
British journal of pharmacology 1981;73(1):65-74.
1981: Ben-Harari R R; Youdim M B
Ontogenesis of uptake and deamination of 5-hydroxytryptamine, dopamine and beta-phenylethylamine in isolated perfused lung and lung homogenates from rats.
British journal of pharmacology 1981;72(4):731-7.
1981: Parvez H; Ismahan G; Parvez S; Youdim M B
Regulation of central and peripheral carbohydrate reserves after selective inhibition of enzyme monoamine oxidase: comparison between fed and starved rats.
Journal de pharmacologie 1981;12(2):123-33.
1981: Barkey R J; Shani J; Lahav M; Amit T; Youdim M B
Effect of prolactin and prostaglandins on the stimulation of prolactin binding sites in the male rat liver.
Molecular and cellular endocrinology 1981;21(2):129-38.
1981: Youdim M B; Oppenheim B
The effect of tryptolines (1, 2, 3, 4-tetrahydro-beta-carbolines) on monoamine metabolism and the platelet aggregation response in human platelets.
Neuroscience 1981;6(4):801-10.
1981: Yehuda S; Youdim M B
Effects of TRH and PS-24 on colonic temperature and motor activity of rats: possible role of dopamine.
Peptides 1981;2(2):131-5.
1980: Mendlewicz J; Youdim M B
Antidepressant potentiation of 5-hydroxytryptophan by L-deprenil in affective illness.
Journal of affective disorders 1980;2(2):137-46.
1980: Youdim M B; Green A R; Bloomfield M R; Mitchell B D; Heal D J; Grahame-Smith D G
The effects of iron deficiency on brain biogenic monoamine biochemistry and function in rats.
Neuropharmacology 1980;19(3):259-67.
1980: Oppenheim B; Hefez A; Youdim M B
Serotonin receptor site in human platelets from control and chlorpromazine treated subjects.
Progress in biochemical pharmacology 1980;16():119-32.
1980: Youdim M B; Bakhle Y S; Ben-Harari R R
Inactivation of monoamines by the lung.
Ciba Foundation symposium 1980;78():105-28.
1980: Lavie P; Wajsbort J; Youdim M B
Deprenyl does not cause insomnia in parkinsonian patients.
Communications in psychopharmacology 1980;4(4):303-7.
1980: Youdim M B
Biochemical characterization of the active site of brain monoamine oxidase.
Monographs in neural sciences 1980;7():176-92.
1980: Coleman R; Youdim M B
Ultrastructural observations on some unusual lamellar bodies associated with human platelets.
Acta haematologica 1980;63(3):162-6.
1980: Youdim M B
Monoamine oxidase inhibitors as anti-depressant drugs and as adjunct to L-dopa therapy of Parkinson's disease.
Journal of neural transmission. Supplementum 1980;(16):157-61.
1979: Salach J I; Detmer K; Youdim M B
The reaction of bovine and rat liver monoamine oxidase with [14C]-clorgyline and [14C]-deprenyl.
Molecular pharmacology 1979;16(1):234-41.
1979: Youdim M B; Aronson J K; Blau K; Green A R; Grahame-Smith D G
Tranylcypromine ('Parnate') overdose: measurement of tranylcypromine concentrations and MAO inhibitory activity and identification of amphetamines in plasma.
Psychological medicine 1979;9(2):377-82.
1979: Oppenheim B; Youdim M B
A nucleotide with characteristic platelet aggregation and inhibition properties similar to 5-hydroxytryptamine [proceedings]
British journal of pharmacology 1979;66(1):94P.
1979: Bakhle Y S; Youdim M B
The metabolism of 5-hydroxytryptamine and beta-phenylethylamine in perfused rat lung and in vitro.
British journal of pharmacology 1979;65(1):147-54.
1979: Parvez H; Ismahan G; Parvez S; Youdim M B
Developmental changes in the activity of catechol-O-methyl transferase in rat and rabbit fetuses.
Journal of neural transmission 1979;44(1-2):65-75.
1978: Youdim M B; Green A R
Iron deficiency and neurotransmitter synthesis and function.
The Proceedings of the Nutrition Society 1978;37(2):173-9.
1978: Mendlewicz J; Youdim M B
Anti-depressant potentiation of 5-hydroxytryptophan by L-deprenyl, an MAO "type B" inhibitor.
Journal of neural transmission 1978;43(3-4):279-86.
1978: Riederer P; Youdim M B; Rausch W D; Birkmayer W; Jellinger K; Seemann D
On the mode of action of L-deprenyl in the human central nervous system.
Journal of neural transmission 1978;43(3-4):217-26.
1978: Youdim M B
The active centers of monoamine oxidase types "A" and "B": binding with (14C)-clorgyline and (14C)-deprenyl.
Journal of neural transmission 1978;43(3-4):199-208.
1978: Riederer P; Youdim M B; Birkmayer W; Jellinger K
Monoamine oxidase activity during (--)-deprenil therapy: human brain post-mortem studies.
Advances in biochemical psychopharmacology 1978;19():377-82.
1978: Parvez S; Ismahan G; Raza-Bukhari A; Youdim M B
Activity of catechol-o-methyltransferase in brain regions and adrenal gland during the oestrus cycle.
Journal of neural transmission 1978;42(4):305-12.
1978: Parvez S; Ismahan G; Raza-Bukhari A; Parvez H; Youdim M B
Central and peripheral catecholamines and phenylethanolamine-N-methyl-transferase activity during the oestrus cycle.
Journal of neural transmission 1978;42(4):293-304.
1978: Ismahan G; Parvez H; Parvez S; Youdim M B
The effect of selective monoamine oxidase inhibitors, clorgyline and deprenyl, upon tissue glycogen stores and blood glucose levels.
Journal of neural transmission. Supplementum 1978;(14):143-52.
1977: Lees A J; Shaw K M; Kohout L J; Stern G M; Elsworth J D; Sandler M; Youdim M B
Deprenyl in Parkinson's disease.
Lancet 1977;2(8042):791-5.
1977: Mendlewicz J; Youdim M B
Monoamine-oxidase inhibitors and prolactin secretion.
Lancet 1977;2(8036):507.
1977: Green A R; Mitchell B D; Tordoff A F; Youdim M B
Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytryptamine.
British journal of pharmacology 1977;60(3):343-9.
1977: Ismahan G; Parvez H; Parvez S; Youdim M B
Comparative effects of hypophysectomy and adrenalectomy upon plasma and adrenal monoamines in pregnant and non-pregnant rats.
British journal of pharmacology 1977;60(3):385-91.
1977: Youdim M B
Pica hypothesis.
British journal of haematology 1977;36(2):298.
1977: Green A R; Youdim M B
The effect of iron deficiency on brain monoamine metabolism and the behavioural responses to increased brain 5-hydroxytryptamine and dopamine synthesis [proceedings].
British journal of pharmacology 1977;59(3):470P-471P.
1977: Parvez H; Parvez S; Raza-Bukhari A; Youdim M B
Differences in effects of hypophysectomy, adrenalectomy and thyroidectomy upon blood glucose concentration and maintenance of adrenal weight during pregnancy and estrus cycle. Influence of ACTH, hydrocortisone and thyroxine administration.
Annales d'endocrinologie 1977;38(2):99-110.
1977: Birkmayer W; Riederer P; Ambrozi L; Youdim M B
Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study.
Lancet 1977;1(8009):439-43.
1977: Woods H F; Youdim M B
The isolated perfused rat brain preparation--a critical assessment.
Essays in neurochemistry and neuropharmacology 1977;2():49-69.
1977: Youdim M B; Holzbauer M
Are there MAO inhibitors specific for dopamine metabolism?
Advances in biochemical psychopharmacology 1977;16():349-58.
1976: Woods H F; Youdim M B; Boullin D; Callender S
Monoamine metabolism and platelet function in iron-deficiency anaemia.
Ciba Foundation symposium 1976;(51):227-48.
1976: Youdim M B; Green A R
Biogenic monoamine metabolism and functional activity in iron-deficient rats: behavioural correlates.
Ciba Foundation symposium 1976;(51):201-25.
1976: Blau K; Goodwin B; Woods H F; Youdim M B
Phenylethylamine formation in perfused rat liver [proceedings].
British journal of pharmacology 1976;58(3):474P.
1976: Ambrozi L; Birkmayer W; Riederer P; Youdim M B
L-dopa and (-)-deprenil in the treatment of Parkinson's disease: a long-term study [proceedings].
British journal of pharmacology 1976;58(3):423P-424P.
1976: Parvez S; Parvez H; Youdim M B
Adrenal-pituitary implication for maintenance of tissue glycogen stores in cyclic and pregnant rats.
Journal of steroid biochemistry 1976;7(9):653-9.
1976: Woods H F; Graham C W; Green A R; Youdim M B; Grahame-Smith D G; Hughes J T
Some histological and metabolic properties of an isolated perfused rat brain preparation with special reference to monoamine metabolism.
Neuroscience 1976;1(4):313-23.
1976: Parvez S; Youdim M B; Parvez H
Influence of thyroidectomy and compensatory treatment with L-thyroxine upon tissue glycogen stores during last part of pregnancy in the rat.
Pharmacological research communications 1976;8(3):309-18.
1976: Youdim M B; Grahame-Smith D G; Woods H F
Some properties of human platelet monoamine oxidase in iron-deficiency anaemia.
Clinical science and molecular medicine 1976;50(6):479-85.
1976: Youdim M B
Proceedings: Monoamine oxidase active site; the binding to and titration of monoamine oxidase with (14C)-selective inhibitors.
British journal of pharmacology 1976;56(3):375P.
1976: Green A R; Youdim M B; Grahame-Smith D G
Quipazine: its effects on rat brain 5-hydroxytryptamine metabolism, monoamine oxidase activity and behaviour.
Neuropharmacology 1976;15(3):173-9.
1976: Bakhle Y S; Youdim M B
Metabolism of phenylethylamine in rat isolated perfused lung: evidence for monoamine oxidase 'type B' in lung.
British journal of pharmacology 1976;56(1):125-7.
1976: Youdim M B
Variation in monoamine oxidase activity in rat brain crude mitochondrial fractions prepared by rate zonal centrifugation.
Journal of neural transmission 1976;38(1):UNKNOWN.
1976: Woods H F; Green A R; Youdim M B; Grahame-Smith D G
Monoamine metabolism in the isolated perfused rat brain.
Biochemical Society transactions 1976;4(1):22-6.
1976: Youdim M B; Holzbauer M
Physiological and pathological changes in tissue monoamine oxidase activity.
Journal of neural transmission 1976;38(3-4):193-229.
1975: Green A R; Youdim M B
Effects of monoamine oxidase inhibition by clorgyline, deprenil or tranylcypromine on 5-hydroxytryptamine concentrations in rat brain and hyperactivity following subsequent tryptophan administration.
British journal of pharmacology 1975;55(3):415-22.
1975: Youdim M B; Hamon M; Bourgoin S
Properties of partially purified pig brain stem tryptophan hydroxylase.
Journal of neurochemistry 1975;25(4):407-14.
1975: Boullin D J; Bhagavan H N; Coleman M; O'Brien R A; Youdim M B
Platelet monoamine oxidase in children with infantile autism.
Medical biology 1975;53(4):210-3.
1975: Youdim M B
In vitro inhibition of brain mitochondrial monoamine oxidase by 6-hydroxydopamine.
British journal of pharmacology 1975;54(3):403-5.
1975: Bakhle Y S; Youdim M B
Proceedings: Inactivation of phenylethylamine and 5-hydroxytryptamine in rat isolated lungs: evidence for monoamine oxidase A and B in lung.
The Journal of physiology 1975;248(1):23P-25P.
1975: Blatchford D; Holzbauer M; Youdim M B
Proceedings: Substrate and strain-dependent differences in the development of monoamine oxidase in the rat brain.
British journal of pharmacology 1975;54(2):251P-252P.
1975: Youdim M B; Woods H F; Mitchell B; Grahame-Smith D G; Callender S
Human platelet monoamine oxidase activity in iron-deficiency anaemia.
Clinical science and molecular medicine 1975;48(4):289-95.
1975: Graham C W; Green A R; Woods H F; Youdim M B
5-Hydroxytryptamine synthesis in the isolated perfused rat brain.
British journal of pharmacology 1975;53(3):450P-451P.
1975: Collins G G; Youdim M B
The binding of (14C)phenethylhydrazine to rat liver monoamine oxidase.
Biochemical pharmacology 1975;24(6):703-6.
1975: Parvez S; Parvez S H; Youdim M B
Variation in activity of monoamine metabolizing enzymes in rat liver during pregnancy.
British journal of pharmacology 1975;53(2):241-6.
1975: Youdim M B; Woods H F
The influence of tissue environment on the rates of metabolic processes and the properties of enzymes.
Biochemical pharmacology 1975;24(3):317-23.
1975: Youdim M B; Grahame-Smith D G; Holzbauer M
Effect of age on the development and properties of brain monoamine oxidase.
Biochemical Society transactions 1975;3(5):702-4.
1975: Sandler M; Youdim M B; Hannington E; Corne S J; Stephens R J
Phenylethylamine-oxidizing defect in migraine: circulatory implications.
Clinical and experimental pharmacology & physiology 1975;Suppl 2():79-81.
1975: Birkmayer W; Riederer P; Youdim M B; Linauer W
The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil.
Journal of neural transmission 1975;36(3-4):303-26.
1975: Youdim M B; Holman B
The nature of inhibition of cat brain mitochondrial monoamine oxidase by clorgyline.
Journal of neural transmission 1975;37(1):11-24.
1975: Youdim M B
Monoamine oxidase. Its inhibition.
Modern problems of pharmacopsychiatry 1975;10():65-88.
1975: Youdim M B; Mitchell B; Woods H F
The effect of increasing phenylalanine concentration on phenylalanine metabolism in perfused rat liver.
Biochemical Society transactions 1975;3(5):683-4.
1974: Callender S; Grahame-Smith D G; Woods H F; Youdim M B
Proceedings: Reduction of platelet monoamine oxidase activity in iron deficiency anaemia.
British journal of pharmacology 1974;52(3):447P-448P.
1974: Sandler M; Youdim M B; Hanington E
A phenylethylamine oxidising defect in migraine.
Nature 1974;250(464):335-7.
1974: Sandler M; Youdim M B; Pare C M
Proceedings: Multiple forms of MAO: some in vivo correlations.
Psychopharmacology bulletin 1974;10(3):5-6.
1974: Youdim M B; Holzbauer M; Woods H F
Proceedings: Physico-chemical properties, development, and regulation of central and peripheral monoamine oxidase activity.
Psychopharmacology bulletin 1974;10(3):6-7.
1974: Carter S M; Youdim M B; Sandler M; Hunter K R; Stern G M
Enhanced tyramine conjugation in Parkinson's disease.
Clinica chimica acta; international journal of clinical chemistry 1974;51(3):327-9.
1974: Youdim M B; Hamon M; Bourgoin S
Purification of pig brainstem tryptophan hydroxylase and some of its properties.
Advances in biochemical psychopharmacology 1974;11(0):13-7.
1974: Sandler M; Carter S B; Goodwin B L; Ruthven C R; Youdim M B; Hanington E; Cuthbert M F; Pare C M
Multiple forms of monoamine oxidase: some in vivo correlations.
Advances in biochemical psychopharmacology 1974;12(0):3-10.
1974: Youdim M B; Holzbauer M; Woods H F
Physicochemical properties, development, and regulation of central and peripheral monoamine oxidase activity.
Advances in biochemical psychopharmacology 1974;12(0):11-28.
1974: Sandler M; Youdim M B
Monoamine oxidases: the present status.
International pharmacopsychiatry 1974;9(1):27-34.
1974: Youdim M B
Heterogeneity of rat brain mitochondrial monoamine oxidase.
Advances in biochemical psychopharmacology 1974;11(0):59-63.
1973: Holzbauer M; Youdim M B
The oestrous cycle and monoamine oxidase activity.
British journal of pharmacology 1973;48(4):600-8.
1973: Agid Y; Javoy F; Youdim M B
Monoamine oxidase and aldehyde dehydrogenase activity in the striatum of rats after 6-hydroxydopamine lesion of the nigrostriatal pathway.
British journal of pharmacology 1973;48(1):175-8.
1973: Youdim M B
Multiple forms of mitochondrial monoamine oxidase.
British medical bulletin 1973;29(2):120-2.
1973: Holzbauer M; Bull G; Youdim M B; Wooding F B; Godden U
Subcellular distribution of steroids in the adrenal gland.
Nature: New biology 1973;242(117):117-9.
1973: Javoy F; Youdim M B; Agid Y; Glowinski J
Early effects of monoamine oxidase inhibitors on dopamine metabolism and monoamine oxidase activity in the neostriatum of the rat.
Journal of neural transmission 1973;34(4):279-89.
1972: Tipton K F; Youdim M B; Spires I P
Beef adrenal medulla monoamine oxidase.
Biochemical pharmacology 1972;21(16):2197-204.
1972: Collins G G; Youdim M B; Sandler M
Multiple forms of monoamine oxidase. Comparison of in vitro and in vivo inhibition patterns.
Biochemical pharmacology 1972;21(14):1995-8.
1972: Sandler M; Youdim M B
Multiple forms of monoamine oxidase: functional significance.
Pharmacological reviews 1972;24(2):331-48.
1972: Youdim M B; Collins G G; Sandler M; Bevan Jones A B; Pare C M; Nicholson W J
Human brain monoamine oxidase: multiple forms and selective inhibitors.
Nature 1972;236(5344):225-8.
1972: Holzbauer M; Youdim M B
Proceedings: Influence of endocrine glands on central and peripheral monoamine oxidase activity.
British journal of pharmacology 1972;44(2):355P-356P.
1972: Youdim M B; Sourkes T L
The flavin prosthetic group of purified rat liver mitochondrial monoamine oxidase.
Advances in biochemical psychopharmacology 1972;5():45-53.
1972: Youdim M B; Lagnado J R
Limitation in the use of tetrazolium salts for the detection of multiple forms of monoamine oxidase.
Advances in biochemical psychopharmacology 1972;5():289-92.
1972: Youdim M B
Multiple forms of monoamine oxidase and their properties.
Advances in biochemical psychopharmacology 1972;5():67-77.
1971: Youdim M B; Carter S B; Hanington E; Wilkinson M; Sandler M
Conjugation defect in tyramine-sensitive migraine.
Nature 1971;230(5289):127-8.
1971: Youdim M B; Collins G G; Sandler M
Monoamine oxidase: multiple forms and selective inhibitors.
The Biochemical journal 1971;121(3):34P-36P.
1971: Youdim M B; Collins G G
The dissociation and reassociation of rat liver mitochondrial monoamine oxidase.
European journal of biochemistry / FEBS 1971;18(1):73-8.
1971: Youdim M B
Rat liver mitochondrial monoamine oxidase, a flavin-containing enzyme.
The Biochemical journal 1971;121(1):20P.
1971: Papeschi R; Sourkes T L; Youdim M B
The effect of yohimbine on brain serotonin metabolism, motor behavior and body temperature of the rat.
European journal of pharmacology 1971;15(3):318-26.
1970: Carter S B; Karoum F; Sandler M; Youdim M B
The effect of tyramine on phenolic acid and alcohol excretion in man.
British journal of pharmacology 1970;39(1):202P-203P.
1970: Carter S B; Karoum F; Sandler M; Youdim M B
The promotion of phenolic alcohol formation in man by reserpine and ethanol.
British journal of pharmacology 1970;39(1):200P-202P.
1970: Collins G G; Youdim M B
Multiple forms of human brain monoamine oxidase: substrate specificities.
The Biochemical journal 1970;117(2):43P.
1970: Youdim M B; Collins G G
Dissociation and reassociation of rat liver mitochondrial monoamine oxidase.
The Biochemical journal 1970;117(2):37P.
1970: Collins G G; Sandler M; Williams E D; Youdim M B
Multiple forms of human brain mitochondrial monoamine oxidase.
Nature 1970;225(5235):817-20.
1969: Symes A L; Sourkes T L; Youdim M B; Gregoriadis G; Birnbaum H
Decreased monoamine oxidase activity in liver of iron-deficient rats.
Canadian journal of biochemistry 1969;47(11):999-1002.
1969: Collins G G; Youdim M B
Further properties of multiple forms of mitochondrial monoamine oxidase.
The Biochemical journal 1969;114(4):80P.
1969: Youdim M B; Collins G G; Sandler M
Multiple forms of rat brain monoamine oxidase.
Nature 1969;223(5206):626-8.
1968: Sandler M; Youdim M B
The effect of tyramine, reserpine and other drugs on catecholamine metabolism in man.
British journal of pharmacology 1968;34(1):224P-225P.
1968: Youdim M B; Sandler M
Activation of monoamine oxidase and inhibition of aldehyde dehydrogenase by reserpine.
European journal of pharmacology 1968;4(1):105-7.
1968: Sandler M; Youdim M B
Promotion of 4-hydroxy-3-methoxyphenylglycol formation in man by reserpine.
Nature 1968;217(5130):771-2.
1966: Youdim M B; Sourkes T L
Properties of purified, soluble monoamine oxidase.
Canadian journal of biochemistry 1966;44(10):1397-400.

Sign-in to see more